Document:

exv10w31

Exhibit 10.31

EXECUTION VERSION

CLIENT TRANSITION AGREEMENT

     This CLIENT TRANISITION AGREEMENT (the “Agreement”) is made and entered into as of
February ___, 2009 between eHealthInsurance Services, Inc., a Delaware corporation
(“eHealth”) and Health Benefits Direct Corporation, a Delaware corporation and its wholly
owned subsidiary HBDC II, Inc, also a Delaware Corporation (collectively, “HBDC”).

RECITALS

     A. HBDC or an employee or former employee sales agent serves as broker of record for a number
of individual and family major medical (“IFP”) health insurance policies and ancillary
policies (e.g., dental, life and vision insurance) sold along or bundled with such policies
(collectively, the “Policies”).

     B. HBDC desires to transfer to eHealth broker of record (“BOR”) status and the right
to receive commissions on all of the in-force Policies issued by the Specified Carriers, including
those issued after the date hereof, but excluding the Excluded Policies (collectively, the
“Transition Policies”).

     C. eHealth desires to compensate HBDC, as described in this Agreement, for the transfer of BOR
status and the right to receive commissions on the Transition Policies.

     NOW, THEREFORE, in consideration of the covenants, promises and representations set forth
herein, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties agree as follows:

ARTICLE I

DEFINITIONS

     1.1 Capitalized Terms. The following capitalized terms shall have the meanings set forth below:

          (a) “Acquisition Proposal” shall have the meaning set forth in Section 6.5.

          (b) “Action or Proceeding” shall mean any action, suit, proceeding, arbitration or
governmental or regulatory investigation or audit.

          (c) “Agreement” shall have the meaning set forth in the preamble above, together with
all exhibits and schedules hereto.

          (d) “Ancillary Agreements” shall mean the Marketing and Referral Agreement and the
Collateral Agreements.

 

 

          (e) “Assumed Obligations” shall have the meaning set forth in Section 2.5.

          (f) “Books and Records” shall mean all papers and records (in paper or electronic
format) in the care, custody or control of HBDC relating to the Transition Policies, including the
applications for the Transition Policies, the full names, addresses (including Zip Code), e-mail
addresses, dates of birth, gender and tobacco usage information (yes/no) of the holders of the
Transition Policies, and any and all opt-out lists pertaining to the holders of the Transition
Policies, in such electronic form and format as may be reasonably requested by eHealth.

          (g) “BOR” shall have the meaning set forth in Recital B.

          (h) “Business” shall have the meaning set forth in Section 4.1.

          (i) “Carrier Book” shall mean with respect to a particular Specified Carrier all of
the Transition Policies issued by that Specified Carrier.

          (j) “Collateral Agreements” shall have the meaning set forth in Section 2.4.

          (k) “Closing” shall have the meaning set forth in Section 3.1.

          (l) “Closing Date” shall have the meaning set forth in Section 3.1.

          (m) “Conflict” shall mean any event that would constitute a conflict, breach,
violation or default (with or without notice or lapse of time, or both) or give rise to a right of
termination, cancellation, modification or acceleration of any obligation or loss of any benefit.

          (n) “Confidentiality Agreement” shall mean the Reciprocal Non-Disclosure Agreement
between eHealth and HBDC dated April 1, 2008.

          (o) “Contract” shall mean any mortgage, indenture, lease, contract, purchase order,
covenant or other agreement, instrument or commitment, permit, concession, franchise or license.

          (p) “eHealth shall have the meaning set forth in the preamble above.

          (q) “Estimated Lifetime Value” shall mean with respect to a Specified Carrier’s
Carrier Book the value of such Carrier Book as determined and agreed upon by eHealth and HBDC. The
Estimated Lifetime Value shall equal the difference between (i) the anticipated regular commission
payments to eHealth on the Specified Carrier’s Carrier Book for in-force Transition Policies
between February 1, 2009 and January 31, 2014 as a result of the BOR Transfer relating to such
Specified Carrier; and (ii) the amount of the Assumed Obligation for historical commission
advances made by such Specified Carrier to HBDC (if any).

          (r) “Exchange Act” shall mean the Securities Exchange Act of 1934, as
amended.

          (s) “Excluded Liabilities” shall have the meaning set forth in
Section 2.6.

          (t) “Excluded Policies” shall have the meaning set forth in Section
2.2.

-2-

 

          (u) “Governmental Entity” shall mean any U.S. or foreign, national, federal, state,
municipal or local or other government, court, administrative agency or commission, court tribunal
or judicial or arbitral body or other governmental body, authority, instrumentality, agency or
commission.

          (v) “HBDC” shall have the meaning set forth in the preamble above.

          (w) “IFP” shall have the meaning set forth in Recital A.

          (x) “Indemnification Claim” shall have the meaning set forth in Section 8.3.

          (y) “Indemnification Objection Notice” shall have the meaning set forth in Section
8.3.

          (z) “Initial BOR Transfer Payment” shall mean, with respect to each Carrier Book that
is a part of the BOR Transfer, twenty percent (20%) of the Estimated Lifetime Value of such Carrier
Book.

          (aa) “Lead” shall mean shall mean health insurance prospect or member information
belonging to HBDC.

          (bb) “Lead Database” shall mean the full names, addresses (including Zip Code), date
of birth, gender and tobacco usage information (yes/no) and e-mail addresses of all of the Leads in
the possession of HBDC or any Subsidiary of HBDC as of the first Closing, and any and all opt-out
lists pertaining to such Leads, in such electronic form and format as may be reasonably requested
by eHealth

          (cc) “Liability” shall mean any liability or obligation (whether known or unknown,
whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued,
whether liquidated or unliquidated, whether incurred or consequential and whether due or to become
due), including any liability for taxes.

          (dd) “Lien” shall mean any pledge, lien, security interest, charge, claim, equity,
encumbrance, restriction on transfer, conditional sale or other title retention device or
arrangement (including a capital lease), transfer for the purpose of subjection to the payment of
any indebtedness, or restriction on the creation of any of the foregoing, whether relating to any
property or right or the income or profits therefrom.

          (ee) “Loss” shall have the meaning set forth in Section 8.2.

          (ff) “Marketing and Referral Agreement” shall mean the Marketing and Referral
Agreement between eHealth and HBDC, the form of which is attached hereto as Schedule
1.1(ff).

          (gg) “Nasdaq” means the Nasdaq Global Market.

          (hh) “Officer’s Certificate” shall have the meaning set forth in Section
7.2(d).

-3-

 

          (ii) “Ordinary Course of Business” shall mean the ordinary course of business,
consistent with past practice (including with respect to quantity and frequency).

          (jj) “Person” shall mean any individual, partnership, firm, corporation, association,
trust, unincorporated organization or other entity, as well as any syndicate or group of any of the
foregoing.

          (kk) “Policies” shall have the meaning set forth in Recital A.

          (ll) “Purchaser Indemnified Parties” shall have the meaning set forth in Section
8.2.

          (mm) “SEC” means the Securities and Exchange Commission.

          (nn) “Securities Act” shall mean the Securities Act of 1933, as amended.

          (oo) “Specified Carriers” shall mean Aetna, Inc., Golden Rule Insurance Company
(“GRIC”), Humana, Inc., PacifiCare, Inc., Time Insurance Company (marketed under the brand
name Assurant Health) and United Healthcare Insurance Co..

          (pp) “Subsidiary” or “Subsidiaries” shall mean, with respect to any Person,
any entity of which securities or other ownership interests having ordinary voting power to elect a
majority of the board of directors or other persons performing similar functions are at any time
directly or indirectly owned by such Person.

          (qq) “Third Party Claim” shall have the meaning set forth in Section 8.5.

          (rr) “Transition Assets” shall mean the BOR Transfer, the Books and Records and the
Lead Database.

          (ss) “Transition Policies” shall have the meaning set forth in Recital B.

     Other capitalized terms shall have the meaning ascribed to such terms in other portions of
this Agreement.

     1.2 Construction.

          (a) As used in this Agreement, the words “include” and “including” and variations thereof will
not be deemed to be terms of limitation, but rather will be deemed to be followed by the words
“without limitation.”

          (b) Except as otherwise indicated, all references in this Agreement to “Articles,”
“Schedules,” and “Sections” are intended to refer to Articles, Schedules, and Sections to this
Agreement.

          (c) The headings in this Agreement are for convenience of reference only, will not be deemed
to be a part of this Agreement, and will not be referred to in connection with the construction or
interpretation of this Agreement.

-4-

 

ARTICLE II

CLIENT TRANSITION

     2.1 BOR Transfer/Books and Records. In one or more Closings and subject to the terms
and conditions set forth in this Agreement (including the conditions to Closing set forth in
Article VII), HBDC shall transfer and assign to eHealth, or shall cause to be transferred
and assigned to eHealth, free and clear of any and all Liens (other than Assumed Obligations) the
following: (i) BOR status on, and all right to receive commissions on premiums paid for, all
Transition Policies (collectively, the “BOR Transfer”); and (ii) the Books and Records. As
more fully described in Article III, the BOR Transfer may take place in successive Closings
on a Carrier Book basis.

     2.2 Excluded Policies. The Transition Policies shall not include, and HBDC shall not
transfer and assign to eHealth, BOR status and the right to receive commissions on (a) any policy,
including any ancillary policy, underwritten by a carrier other than a Specified Carrier; (b) the
policies listed on Exhibit A to HBDC’s BOR letters to the Specified Carriers dated January
22, 2009; or (c) any policy identified as and for which commissions are paid by a Specified Carrier
as a Short Term policy (collectively, the “Excluded Policies”).

     2.3 Transfer of Lead Database. In the first Closing, HBDC shall deliver, assign and
transfer the Lead Database to eHealth in such electronic format as reasonably requested by eHealth.

     2.4 Assignments. HBDC shall deliver or cause to be delivered to eHealth, duly
executed by HBDC, or any other Person required, such other good and sufficient instruments of
assignment and transfer, in form and substance reasonably acceptable to eHealth, as shall be
effective to vest in eHealth BOR status on, and all right to receive commissions on premiums paid
for, all Transition Policies, including without limitation any BOR letter or other agreement or
document requested by a Specified Carrier (such instruments being collectively referred to herein
as the “Collateral Agreements”).

     2.5 Assumed Obligations. As of the Closing of that portion of the BOR Transfer
relating to a Specified Carrier’s Carrier Book, eHealth hereby agrees to assume the following, and
only the following, obligations of HBDC to such Specified Carrier (collectively, the “Assumed
Obligations”): 

     eHealth shall assume the Liabilities of HBDC to the Specified Carrier up to the amounts set
forth on Schedule 2.5 for historical commission advances on Transition Policies made by the
Specified Carrier to HBDC (the “Limited Commission Advance Liability”). eHealth shall
assume the Limited Commission Advance Liability only to the extent such Liability is offset against
commission payments that would otherwise have been made to eHealth on the Transition Policies
(excluding Excluded Policies) of the Specified Carrier and that such offset is consistent with such
Specified Carrier’s commission advance offset practices with HBDC prior to the date of this
Agreement.

     2.6 Liabilities Not Assumed. Other than the Assumed Obligations, eHealth shall not
assume by virtue of this Agreement, and shall have no liability or obligation for, any Liability of
HBDC or its Subsidiaries (the “Excluded Liabilities”), including (without limitation) the
Excess GRIC

-5-

 

Liability and the other Liabilities listed below, and HBDC shall retain and pay, satisfy,
discharge and perform all such Liabilities, including (without limitation) the following Excluded
Liabilities:

          (a) The Liability of HBDC for commission advances other than as specifically set forth in
Section 2.5, including without limitation the Liability of HBDC to GRIC for commission
advances or other amounts in excess of the amount set forth on Schedule 2.5 (the
“Excess GRIC Liability”). .

          (b) Any Liability of HBDC as a result of any Action or Proceeding initiated at any time to the
extent caused by any action or inaction that occurred or condition that existed on or prior to the
Closing Date;

          (c) Any Liability of HBDC for costs and expenses incurred in connection with this Agreement
and the transactions contemplated hereby;

          (d) Any Liability of HBDC under any Contract;

          (e) Any Liability pertaining to HBDC’s business and arising out of or resulting from
noncompliance on or prior to the Closing Date with any laws, statutes, ordinances, rules,
regulations, orders, determinations, judgments or directives, whether legislatively, judicially or
administratively promulgated;

          (f) Any Liability in respect of accounts payable, or payable obligations of HBDC (except as
expressly set forth in Section 2.5);

          (g) Any Liability for taxes of HBDC or any of its Subsidiaries for any taxable period or
portion thereof, or relating or attributable to the Transition Policies or the Lead Database for
any taxable period or portion thereof, ending on and including the Closing Date; eHealth will be
liable for any taxes for any taxable period or portion thereof, or relating or attributable to the
Transition Policies or the Lead Database for any taxable period or portion thereof, beginning on
and including the day after the Closing Date; and

          (h) Any Liability of any Subsidiary of HBDC.

ARTICLE III

CLOSING AND CONSIDERATION

     3.1 Closing. Any Closing of the transactions contemplated by this Agreement (the
“Closing”) will take place at the offices of eHealth, 440 East Middlefield Road, Mountain
View, California 94043, commencing at 9:00 a.m., Pacific Standard Time, two business days following
the satisfaction or written waiver of the last of the conditions of Closing as set forth in
Article VII hereof, or on such other date and time as the parties may mutually determine
(the “Closing Date”). If the conditions to Closing (as set forth in Article VII),
as they relate to that portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book,
are satisfied (or waived in writing), the parties shall hold successive Closings and each such
Closing shall relate to that portion of the BOR Transfer that relates to such Carrier Book and for
which the conditions to Closing are satisfied (or

-6-

 

waived in writing). Under such circumstances, the Books and Records relating to the Transition
Policies (or holders thereof) of such Specified Carrier shall be assigned and transferred at the
same Closing. The date of each successive closing shall be a Closing Date.

     3.2 Consideration. In addition to assuming Assumed Obligations, as consideration for
the BOR Transfer (or portion thereof occurring at a Closing) and the covenants of HBDC:

          (a) Initial BOR Transfer Payment. eHealth shall pay to HBDC II (by wire transfer in
accordance with written instructions delivered by HBDC to eHealth at a Closing) within 2 days after
the Closing of a portion of the BOR Transfer relating to a Specified Carrier’s Carrier Book, the
Initial BOR Transfer Payment relating to such Specified Carrier’s Carrier Book. Notwithstanding
the foregoing, eHealth may pay $966,097 to GRIC in connection with the Closing of the BOR Transfer
relating to GRIC, PacifiCare, Inc. and United Healthcare Insurance Co. Transition Policies (the
“GRIC Closing Payment”). In the event eHealth makes such payment, the Initial BOR Transfer
Payment that eHealth is required to make to HBDC II shall be reduced by the amount of the GRIC
Closing Payment.

          (b) Transition Policy Commission Payments. Subject to the other provisions of this
Agreement, and after the BOR Transfer relating to the Carrier Book of a Specified Carrier, eHealth
shall pay to HBDC II an amount equal to forty-five percent (45%) of each commission payment
received by eHealth and reported by the Specified Carrier as relating to a Transition Policy (a
“Transition Commission Payment”) for the duration of the policy, provided that eHealth
remains BOR on such Transition Policy. For purposes of calculating the Transition Commission
Payment, eHealth shall not be deemed to receive any amount withheld by a Specified Carrier in
satisfaction of an Assumed Obligation or an Excluded Liability.

     3.3 Insurance Licenses. HBDC II covenants that HBDC II holds a validly issued health
insurance agency license in good standing and is authorized to sell health insurance products in
all jurisdictions in the United States. HBDC II shall complete and return to eHealth a Form W-9
and the Affiliate Licensing Form attached hereto as Schedule 3.3, along with copies of all
of its licenses or other satisfactory evidence of licensure. HBDC II further agrees that within
fifteen (15) days of its receipt of any additional health insurance agency license(s), it will
notify eHealth in writing and provide eHealth with a copy of such license(s). HBDC II shall notify
eHealth promptly in writing of any suspension, revocation, termination or non-renewal of any
insurance license or the commencement of any proceeding therefore. HBDC II understands and agrees
that it must comply with this Section 3.3 and that eHealth must be reasonably satisfied
with HBDC II’s licensing documents and licensing status in order for HBDC to be paid Transition
Commission Payments in accordance with Section 3.2(b). Without limiting the foregoing,
HBDC II shall not be entitled to receive Transition Commission Payments if it is not appropriately
licensed in the relevant jurisdiction and eHealth shall not pay Transition Commission Payments
retroactively. Accordingly, to be eligible for Transition Commission Payments for any calendar
month, HBDC II must have submitted to eHealth the appropriate licensing documents no later than the
15th day of such month. Notwithstanding, if eHealth is aware of a failure by HBDC II to
comply with this Section 3.3, eHealth will notify HBDC II in accordance with Section
10.1 of such failure and will not withhold Transition Commission Payments if such failure is
cured by HBDC II within 15 days of notice by eHealth.

-7-

 

     3.4 Timing and Reporting of Transition Commission Payments. Transition Commission
Payments are due and payable on a monthly basis, and shall be paid to HBDC on or before the
thirtieth (30th) day following the last day of the month in which the Transition
Commission Payment is earned. Transition Commission Payments will be paid by wire transfer in
accordance with written instructions delivered by HBDC to eHealth at a Closing or as may be revised
by HBDC from time to time. Transition Commission Payments are earned when eHealth receives a
commission payment accurately reported by a Specified Carrier as a commission on a Transition
Policy (a “Transition Policy Commission”). Transition Commission Payments shall be
accompanied by a statement (a “Transition Commission Payment Statement”) in both paper and
mutually agreeable electronic forms setting forth the calculation of the Transition Commission
Payments. Subject to eHealth’s receipt of accurate, complete and timely commission payment data
from each Specified Carrier, the Transition Commission Payment Statements shall include, at a
minimum (a) the total compensation eHealth received from the Specified Carriers for the Transition
Policies for the reported month, (b) the total Transition Commission Payments owed and paid to
HBDC for such month, and (c) for each underlying Transition Policy, the name of the Specified
Carrier, the commissions received from the Specified Carrier for the reported month, the number of
holders of Transition Policies for which commissions were paid, and the name and address of the
primary applicant underlying such Transition Policy.

     3.5 Transition Commission Payment Offset. eHealth shall be entitled to offset against
amounts owed to HBDC the amount of any prior Transition Commission Payment made by eHealth to HBDC
as a result of eHealth’s receipt of a Transition Policy Commission that a Specified Carrier
contends was not owed or paid in error due to cancellation of the underlying health insurance
policy or otherwise.

     3.6 Right to Audit. HBDC shall have the right to have HBDC employees and/or mutually
agreeable external auditors audit the books and records of eHealth related to this agreement up to
once a year, to determine eHealth’s compliance and adherence to Section 3.2
(Consideration), Section 3.4 (Timing and Reporting of Transition Commission Payments), =
Section 3.5 (Transition Commission Payment Offset) and Section 6.14 (eHealth
Receipt of Commission Payments) of this Agreement. HBDC shall give eHealth reasonable prior
notice of any such audit, and shall abide by reasonable security and confidentiality procedures
during the audit. HBDC shall bear the cost of such audit. eHealth shall have the same right to
audit HBDC in accordance with this Section to determine HBDC’s compliance and adherence to
Section 6.13 (HBDC Receipt of Commission Payments).

     3.7 Retention of Records. eHealth shall retain all records relating to its
performance under this Agreement for six years, or for such period as may be required by applicable
law.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF HBDC

     HBDC hereby represents and warrants to eHealth, subject to the specific exceptions disclosed
in the disclosure letter and schedules thereto (each referencing or cross-referencing the
appropriate Section and paragraph numbers of this Article IV as to which an exception
exists and

-8-

 

which exceptions and other information provided in the disclosure letter and schedules thereto
shall constitute representations and warranties under this Agreement) delivered by HBDC to eHealth,
and dated as of the date hereof (the “HBDC Disclosure Schedule”), as follows:

     4.1 Organization. 

          (a) Health Benefits Direct Corporation and HBDC II, Inc. (collectively HBDC) are both
corporations duly organized, validly existing and in good standing under the laws of the State of
Delaware. HBDC has the power and authority to own, lease and operate its assets and property and
to carry on its business as now being conducted and is duly qualified or licensed to do business,
to perform its obligations as BOR and to receive commission payments for the Transition Policies
and is in good standing in each jurisdiction where the character of the properties owned, leased or
operated by it or the nature of its activities makes such qualification or licensing necessary.

          (b) No other Subsidiary of HBDC is or has been engaged in the operation of the business
relating to the sale of the Transition Policies (the “Business”) or has or ever had any
right to receive commissions as a result of the sale of the Transition Policies. To the extent
that any of the Transition Assets have been transferred to HBDC, such transfer was duly authorized
by all required corporate action, did not result in a Conflict with any law, rule or regulation,
did not breach, violate, create any default or event of default or otherwise result in a Conflict
with any agreement, and did not result in the creation of any Lien. No such transfer resulted or
will result in any claim that such transfer was invalid or conflicted with the rights of any
creditor of HBDC or any other person or entity.

     4.2 Authority. HBDC has all requisite corporate power and authority to enter into
this Agreement and the Ancillary Agreements and to consummate the transactions contemplated hereby
and thereby. The execution and delivery of this Agreement and the Ancillary Agreements and the
consummation of the transactions contemplated hereby and thereby have been duly authorized by all
necessary corporate action on the part of HBDC, and no further action is required on the part of
HBDC or any of HBDC’s stockholders to approve this Agreement, the Ancillary Agreements and the
transactions contemplated hereby and thereby. This Agreement and the Ancillary Agreements and the
transactions contemplated hereby and thereby have been approved by the Board of Directors of HBDC.
This Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby
are not required to be approved by the stockholders of HBDC or the Board of Directors or
stockholders of any Subsidiary of HBDC. This Agreement has, and upon their execution the Ancillary
Agreements will be, duly and validly executed and delivered by HBDC and constitute a valid and
binding obligation of HBDC, enforceable against HBDC in accordance with their terms.

     4.3 No Conflict. The execution and delivery of this Agreement by HBDC does not, and
the execution and delivery of the Ancillary Agreements and the performance of this Agreement and
the Ancillary Agreements will not (a) conflict with or violate the certificate of incorporation or
bylaws of HBDC or any Subsidiary of HBDC; (b) conflict with or violate any law, rule, regulation,
order, judgment or decree applicable to HBDC or any Subsidiary of HBDC or by which any of their
properties are bound or affected; (c) result in the creation of a Lien; or (d) result in any breach
of or constitute a default (or an event that with notice or lapse of time or both would become a
default) under, or impair the rights of HBDC or alter the rights or obligations of any third party
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
note, bond,

-9-

 

mortgage, indenture, Contract, agreement, lease, license, permit, franchise, concession or
other instrument or obligation (including any privacy policy or other privacy obligation pursuant
to which any information to be transferred to eHealth has been collected), to which HBDC or any of
its Subsidiaries is a party or by which the Transition Assets are bound or affected.

     4.4 Indebtedness; Guaranties. Except as set forth on Schedule 2.5 of this
Agreement, neither HBDC nor any of its Subsidiaries has any Liability relating to any of the
Transition Policies or Transition Assets. Neither HBDC nor any of its Subsidiaries is a guarantor
or otherwise liable for any Liability or obligation of any other person or entity for any matter
which relates to or affects or will affect the Transition Policies or Transition Assets or
eHealth’s right to receive commissions as a result of the BOR Transfer.

     4.5 Absence of Changes. Since December 31, 2008 and except as contemplated by this
Agreement, HBDC has conducted the Business only in the Ordinary Course of Business and, without
limiting the generality of the foregoing:

          (a) HBDC has not pledged or otherwise encumbered any of the Transition Assets;

          (b) HBDC has not sold, assigned, licensed, leased, transferred or conveyed, or committed to
sell, assign, license, lease, transfer or convey, any of the Transition Assets;

          (c) The Transition Policies have not been cancelled and HBDC has the right to receive
commissions therefor;

          (d) No Action or Proceeding relating to the Business, the Transition Policies or the
Transition Assets has been commenced or threatened, and to the knowledge of HBDC, no reasonable
basis exists for any litigation, proceeding or investigation relating to the Business, the
Transition Policies or the Transition Assets; and

          (e) There has been no agreement by HBDC, any of its Subsidiaries, or any employees, agents or
affiliates of HBDC or any of its Subsidiaries to do any of the things described in the preceding
clauses (a) through (d) (other than negotiations with eHealth and their representatives regarding
the transactions contemplated by this Agreement).

     4.6 Legal and Other Compliance. The Business has been operated in material compliance
with all applicable laws (including rules, regulations, codes, plans, injunctions, judgments,
orders, decrees, rulings and charges thereunder) of federal, state, local and foreign governments
(and all agencies thereof). No action, suit, proceeding, hearing, investigation, charge,
complaint, claim, demand or notice has been filed or commenced, or to the knowledge of HBDC
threatened against HBDC or any of its Subsidiaries, alleging any failure so to comply, nor to the
knowledge of HBDC, is there any reasonable basis therefor.

     4.7 Liens. Except as set forth on Schedule 2.5 of this Agreement of the HBDC
Disclosure Schedule, HBDC has good and valid title to each of the Transition Assets free and clear
of any Liens. No Liens encumber any Transition Asset. No basis exists for the assertion of any
claim which, if adversely determined, could result in a Lien on any Transition Asset. No Person
other than HBDC possesses any claims or rights with respect to any Transition Asset. 

-10-

 

     4.8 Litigation. There is no Action or Proceeding pending before any court or
administrative agency against HBDC (or any Subsidiary or affiliate of HBDC or any officer or
director of HBDC in their capacity as such) that relates directly or indirectly to the Business or
any Transition Asset or that questions the validity of this Agreement or any Ancillary Agreement or
of any action taken or to be taken pursuant to or in connection with this Agreement or any
Ancillary Agreement. To the knowledge of HBDC, no such Action or Proceeding has been threatened,
and HBDC is not aware of any reasonable basis for any such Action or Proceeding. There are no
judgments, orders, decrees, citations, fines or penalties heretofore assessed against HBDC or any
of its Subsidiaries affecting the Business, any Transition Policy or any Transition Asset under any
federal, state, local or foreign law. 

     4.9 Consents. No consent, waiver, approval, order or authorization of, or
registration, declaration or filing with, or notification to, any Governmental Entity or any third
party (including a Specified Carrier), including a party to any agreement with HBDC or any of its
Subsidiaries (so as not to trigger a Conflict), is required by or with respect to HBDC or any of
its Subsidiaries in connection with the execution and delivery of this Agreement or any Ancillary
Agreement, or the consummation of the transactions contemplated hereby or thereby (including in
order for eHealth to become BOR, and to receive commission payments, on the Transition Policies),
except for the consents listed on Schedule 4.9 of the HBDC Disclosure Schedule.
Schedule 4.9 of the HBDC Disclosure Schedule includes the reason any consents listed
thereon are necessary.

     4.10 Books and Records/Lead Database. The Books and Records (a) are accurate in all
material respects, (b) have been maintained in accordance with applicable laws and regulations and
(c) are in HBDC’s possession or under its control. The Lead Database was obtained in compliance
with all applicable laws, rules and regulations, and the use of the Lead Database by eHealth as
contemplated by the Marketing and Referral Agreement will not cause eHealth to be in violation of
any law, rule or regulation or cause a Conflict with any Contract of HBDC or any of its
Subsidiaries.

     4.11 Solvency. Neither the HBDC nor any of its Subsidiaries has: (a) made a general
assignment for the benefit of creditors, (b) filed any voluntary petition in bankruptcy or suffered
the filing of any involuntary petition by its creditors, (c) suffered the appointment of a receiver
to take possession of all, or substantially all, of its assets, (d) suffered the attachment or
other judicial seizure of all, or substantially all, of its assets, (e) admitted in writing its
inability to pay its debts as they come due, (f) made an offer of settlement, extension or
composition to its creditors generally, or (g) taken any corporate action in furtherance of any of
the foregoing. HBDC is, and after giving effect to the transactions to be effected pursuant to
this Agreement (including the incurrence of all obligations being incurred in connection
herewith), will be immediately following the Closing, Solvent. “Solvent” means, when used
with respect to any Person, that, as of any date of determination: (i) the fair saleable value of
such Person’s assets, as of such date, exceeds the value of its liabilities, including all
contingent and other liabilities, (ii) such Person will not have, as of such date, an unreasonably
small amount of capital for the businesses in which it is engaged or in which management has
indicated it intends to engage, and (iii) such Person will be able to pay its liabilities,
including all contingent and other liabilities, as they mature. For purposes of this definition:
(1) “fair saleable value” means the aggregate amount of net consideration (as of any date
of determination and giving effect to reasonable and customary costs of sale or taxes, where the
probable amount of any such taxes is identified by such Person) that could be expected to be
realized from an interested purchaser by a seller, in an arm’s length transaction under present
conditions in a current market for the sale of assets of a comparable business enterprise, where
both parties are

-11-

 

aware of all relevant facts and neither party is under any compulsion to act, where such
seller is interested in disposing of the entire operation as a going concern, presuming the
business will be continued in its present form and character, and with reasonable promptness, not
to exceed one year; (2) “liabilities, including all contingent and other liabilities” have
the meanings that are generally determined in accordance with applicable federal laws governing
determinations of the insolvency of debtors; (3) “contingent and other liabilities” means
the contingent and other liabilities known to such Person; and (4) “not have an unreasonably
small amount of capital for the businesses in which it is engaged or in which management has
indicated it intends to engage” and “able to pay its liabilities, including all contingent
and other liabilities, as they mature” mean that such Person will be able to generate enough
cash from operations, asset dispositions, refinancing, or a combination thereof, to meet its
obligations (including all contingent and other liabilities) as they become due.

     4.12 Complete Copies of Materials. HBDC has made available to eHealth complete and
correct copies of each document referenced in the HBDC Disclosure Schedule.

     4.13 Liabilities After a Closing. Following the Closing of the BOR Transfer with
respect to a Specified Carrier’s Carrier Book, eHealth will have no Liability to such Specified
Carrier (including interest, penalties or other Liabilities stemming from the commission advance
agreements between HBDC and such Specified Carrier) other than the Assumed Obligation to such
Specified Carrier and Liabilities eHealth would owe to such Specified Carrier had the transactions
contemplated by this Agreement not occurred.

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF EHEALTH

     eHealth hereby represents and warrants to HBDC as follows:

     5.1 Organization and Standing. eHealth is a corporation duly organized, validly
existing and in good standing under the laws of Delaware.  

     5.2 Authority. eHealth has all requisite corporate power and authority to enter into
this Agreement and any Ancillary Agreement to which it is a party and to consummate the
transactions contemplated hereby and thereby. The execution and delivery by eHealth of this
Agreement and such Ancillary Agreements have been duly authorized by all necessary corporate action
on the part of eHealth. This Agreement, and upon their execution any Ancillary Agreement executed
by eHealth will be, duly executed and delivered by eHealth and constitute valid and binding
obligations of eHealth, enforceable against it in accordance with their terms.

     5.3 No Conflict. Except in each case where such conflict, violation or default will
not have a material adverse effect on the legality, validity or enforceability of eHealth’s
obligations under this Agreement or any Ancillary Agreement, neither the execution and delivery of
this Agreement or any Ancillary Agreement to which eHealth is a party, nor the consummation of the
transactions contemplated hereby and thereby, will conflict with or result in any violation of, or
default under (with or without notice or lapse of time, or both) (a) any provision of the
Certificate of Incorporation and Bylaws, each as amended through the date hereof, of eHealth, (b)
any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to eHealth or
its properties or assets, or (c) any

-12-

 

contract, agreement, commitment or undertaking to which eHealth is a party or to which it or
any of its assets or properties are subject or bound.

     5.4 Consents. Other than with respect to consents, waivers, approvals, orders or
authorizations of, or registrations, declarations or filings with, or notifications to, the SEC
and/or Nasdaq, no consent, waiver, approval, order or authorization of, or registration,
declaration or filing with, or notification to, any Governmental Entity is required by or with
respect to eHealth for the execution and delivery of this Agreement, the Ancillary Agreements or
the transactions contemplated hereby and thereby.

     5.5 Solvency. Neither the eHealth nor any of its Subsidiaries has: (a) made a
general assignment for the benefit of creditors, (b) filed any voluntary petition in bankruptcy or
suffered the filing of any involuntary petition by its creditors, (c) suffered the appointment of a
receiver to take possession of all, or substantially all, of its assets, (d) suffered the
attachment or other judicial seizure of all, or substantially all, of its assets, (e) admitted in
writing its inability to pay its debts as they come due, (f) made an offer of settlement, extension
or composition to its creditors generally, or (g) taken any corporate action in furtherance of any
of the foregoing. eHealth is, and after giving effect to the transactions to be effected pursuant
to this Agreement (including the incurrence of all obligations being incurred in connection
herewith), will be immediately following the Closing, Solvent. “Solvent” means, when used with
respect to any Person, that, as of any date of determination: (i) the fair saleable value of such
Person’s assets, as of such date, exceeds the value of its liabilities, including all contingent
and other liabilities, (ii) such Person will not have, as of such date, an unreasonably small
amount of capital for the businesses in which it is engaged or in which management has indicated it
intends to engage, and (iii) such Person will be able to pay its liabilities, including all
contingent and other liabilities, as they mature. For purposes of this definition: (1) “fair
saleable value” means the aggregate amount of net consideration (as of any date of determination
and giving effect to reasonable and customary costs of sale or taxes, where the probable amount of
any such taxes is identified by such Person) that could be expected to be realized from an
interested purchaser by a seller, in an arm’s length transaction under present conditions in a
current market for the sale of assets of a comparable business enterprise, where both parties are
aware of all relevant facts and neither party is under any compulsion to act, where such seller is
interested in disposing of the entire operation as a going concern, presuming the business will be
continued in its present form and character, and with reasonable promptness, not to exceed one
year; (2) “liabilities, including all contingent and other liabilities” have the meanings that are
generally determined in accordance with applicable federal laws governing determinations of the
insolvency of debtors; (3) “contingent and other liabilities” means the contingent and other
liabilities known to such Person; and (4) “not have an unreasonably small amount of capital for the
businesses in which it is engaged or in which management has indicated it intends to engage” and
“able to pay its liabilities, including all contingent and other liabilities, as they mature” mean
that such Person will be able to generate enough cash from operations, asset dispositions,
refinancing, or a combination thereof, to meet its obligations (including all contingent and other
liabilities) as they become due.

-13-

 

ARTICLE VI

ADDITIONAL AGREEMENTS

     6.1 Access Pending the Closing. During the period commencing on the date of this
Agreement and continuing through the earlier of the last Closing pursuant to this Agreement and the
termination of this Agreement pursuant to Article IX, HBDC, upon reasonable prior notice
from eHealth to HBDC, will (i) afford eHealth and its representatives, at all reasonable times
during normal business hours, reasonable access to HBDC’s and its Subsidiaries’ personnel,
professional advisors, properties, contracts, Books and Records and other documents and data
relating to the Transition Policies, the Transition Assets and/or the Assumed Obligations, (ii)
furnish eHealth and its representatives with copies of all Contracts, Books and Records, and other
existing documents and data as eHealth may reasonably request, and (iii) furnish eHealth with such
additional data and information as eHealth may reasonably request, in each case relating to the
Transition Policies, Transition Assets or the Assumed Obligations. No information or knowledge
obtained in any investigation pursuant to this Section 6.1 shall affect or be deemed to
modify any representation or warranty contained herein or the conditions to the obligations of the
parties hereto to consummate the transactions contemplated hereby.

     6.2 Operation of the Business by HBDC. During the period commencing on the date of
this Agreement and continuing through the earlier of the Closing of the last BOR Transfer and any
termination of this Agreement pursuant to Article IX, unless otherwise agreed in writing by
eHealth, HBDC will except as otherwise allowed or required pursuant to the terms of this Agreement:

          (a) conduct the Business in the Ordinary Course of Business in a manner that enables HBDC to
comply with subsections (b) and (c) below and its other obligations under this Agreement. The
Parties understand and agree that HBDC shall not be obligated to market or sell new insurance
policies after the date of this Agreement, except as set forth in the Marketing and Referral
Agreement;

          (b) use commercially reasonable, good faith efforts to maintain the Transferred Policies where
BOR status has not been transferred to eHealth; and

          (c) maintain the Books and Records and the Lead Database in the usual, regular and ordinary
manner, on a basis consistent with prior years.

     6.3 Conduct Prior to Closing. Except as otherwise expressly permitted by this
Agreement, between the date of this Agreement and continuing through the earlier of the Closing of
the last BOR Transfer and any termination of this Agreement pursuant to Article IX, HBDC
will not, take any action, or fail to take any action, as a result of which any of the changes or
events described in Section 4.5 of this Agreement would reasonably be expected to occur.
In addition, HBDC will not, and shall ensure that its Subsidiaries do not, without the prior
written consent of eHealth:

          (a) take any action to impair, encumber, create a Lien against or otherwise adversely affect
the Transition Assets or the Transition Policies;

-14-

 

          (b) other than as described on Schedule 4.5 to the HBDC Disclosure Schedule, propose
or enter into a Contract with any person, other than eHealth, providing for the possible
acquisition, transfer or disposition of the Business or any of the Transition Assets;

          (c) enter into any Contract relating to any of the Transition Policies, Transition Assets or
Assumed Obligations;

          (d) take any action, or fail to take any action, which would result in any of the
representations and warranties set forth in Article IV not being true and correct on and as
of the Closing Date with the same force and effect as if such representations and warranties had
been made on and as of the Closing Date;

          (e) take, or agree in writing or otherwise to take, any of the actions described in
Sections 6.3(a) through (d) above, or any other action that would prevent HBDC from
performing or cause HBDC not to perform its covenants hereunder.

     6.4 Confidentiality. eHealth and HBDC acknowledge that they have entered into a
Confidentiality Agreement and a Nondisclosure and Nonuse Agreement dated November 6, 2008 (the
“NDA”). The NDA shall terminate upon the initial Closing under this Agreement and the
terms of the Confidentiality Agreement shall govern all information shared between eHealth and HBDC
prior to the date of such initial Closing and all information shared after such Closing relating to
this Agreement; provided, however, that the following information shall become “Confidential
Information” (as such term is used in the Confidentiality Agreement) of eHealth under the
Confidentiality Agreement and not “Confidential Information” of HBDC: (i) after the Closing of a
portion of the BOR Transfer relating to a Carrier Book, all non-public information relating to the
Transition Policies (and the holders thereof) that form a part of such Carrier Book and the Books
and Records and Assumed Obligations (if any) relating to such Carrier Book; and (ii) after the
first Closing relating to any portion of the BOR Transfer, the Lead Database. Without limiting the
foregoing, (i) from and after the first Closing hereunder, HBDC shall not use or disclose the Lead
Database (or any information contained therein) for any purpose other than in connection with the
performance of its obligations under this Agreement or the Marketing and Referral Agreement; (ii)
from and after the first Closing hereunder, HBDC shall not disclose the information on Transition
Commission Payment Statements; and (iii) from and after the Closing of a portion of the BOR
Transfer relating to a Carrier Book, HBDC shall not use or disclose the name, e-mail address or
other contact information or personally identifiable information relating to any holder of a
Transition Policy that forms a part of such Carrier Book other than in connection with the
performance of its obligations under this Agreement or the Marketing and Referral Agreement.

     6.5 No Solicitation. From and after the date of this Agreement until the earlier to
occur of the last Closing of a BOR Transfer or termination of this Agreement pursuant to its terms,
HBDC, its Subsidiaries and HBDC’s and its Subsidiaries’ directors, officers, employees,
representatives, investment bankers, agents and affiliates shall not, directly or indirectly (a)
solicit or encourage submission of any Acquisition Proposal (as defined herein) by any person,
entity, or group (other than eHealth and its affiliates, agents and representatives) or (b)
participate in any discussions or negotiations with, or disclose any information concerning the
Transition Assets, or afford access to the properties, books or records with respect to the
Transition Assets, or otherwise assist or facilitate, or enter into any agreement or understanding
with, any person, entity or group (other than eHealth

-15-

 

and its affiliates, agents, and representatives) in connection with any Acquisition Proposal.
For purposes of this Agreement, an “Acquisition Proposal” means any proposal or offer
relating to any sale, acquisition, purchase or license of all or any portion of the Transition
Assets. HBDC will, and will cause its Subsidiaries to, immediately cease and cause to be
terminated any and all existing activities, discussion, or negotiations with any parties conducted
heretofore with respect to any of the foregoing. HBDC will promptly (A) notify eHealth if it or
any of its Subsidiaries receives any written proposal or written inquiry or written request for
information in connection with an Acquisition Proposal or potential Acquisition Proposal and (B)
notify eHealth of the significant terms and conditions of any such Acquisition Proposal including
the identity of the party making an Acquisition Proposal.

     6.6 Notification of Certain Matters. HBDC shall give prompt notice to eHealth of (a)
the occurrence or non-occurrence of any event, the occurrence or non-occurrence of which is likely
to cause any representation or warranty of HBDC contained in this Agreement to be untrue or
inaccurate at or prior to a Closing, and (b) any failure of HBDC to comply with or satisfy any
covenant, condition or agreement to be complied with or satisfied by it hereunder; provided,
however, that the delivery of any notice pursuant to this Section 6.6 shall not (i) limit
or otherwise affect any remedies available to the party receiving such notice or (ii) constitute an
acknowledgment or admission of a breach of this Agreement. No disclosure by HBDC pursuant to this
Section 6.6, however, shall be deemed to amend or supplement the HBDC Disclosure Schedule
or prevent or cure any misrepresentations, breach of warranty or breach of covenant.

     6.7 Public Disclosure. eHealth and HBDC shall consult with each other before issuing
any press release or otherwise making any public statement with respect to this Agreement or any
Ancillary Agreement, eHealth’s acquisition of the Transition Assets, the other party or parties
hereto, or any Acquisition Proposal, and shall not issue any such press release or make any such
public statement prior to such consultation, except as may be required by applicable law or, with
respect to eHealth any rules of or listing agreement with a national securities exchange or Nasdaq.
Notwithstanding the foregoing, neither eHealth or HBDC shall issue any press release relating to
this Agreement, any Ancillary Agreement or HBDC’s relationship with eHealth without the other
party’s prior written consent.

     6.8 Communication with and Service of Holders of Transition Policies. Except with
respect to HBDC’s Ordinary Course of Business communications prior to the date of a BOR Transfer
and any communications by eHealth after a BOR Transfer, eHealth and HBDC shall cooperate and
consult with each other with respect to communications to the holders of Transition Policies. HBDC
shall cooperate with eHealth as reasonably requested by eHealth in connection with any
communications to holders of Transition Policies notifying them of the BOR Transfer. After the BOR
Transfer, eHealth will perform all ongoing broker-related duties and services with respect to the
holders of Transition Policies in accordance with industry standards.

     6.9 Consents. Unless otherwise notified by eHealth in writing, HBDC shall use its
best efforts to obtain the consents, waivers and approvals necessary to effectuate the transactions
contemplated by this Agreement, including under any contractual or other restrictions relating to
the Transition Assets that are necessary to permit the transfer of such Transition Assets to
eHealth in connection with this Agreement. eHealth shall reasonably cooperate with HBDC in its
efforts to obtain such consents, waivers and approvals.

-16-

 

     6.10 Legal Requirements. Each of eHealth and HBDC will take all commercially
reasonable actions necessary to comply promptly with all legal requirements which may be imposed on
such party with respect to this Agreement and the transactions contemplated hereby and will
promptly cooperate with and furnish information to any other party hereto in connection with any
such requirements imposed upon such other party in connection herewith. Each party will take all
commercially reasonable actions to obtain (and will cooperate with the other parties in obtaining)
any consent, authorization, order or approval of, or any registration, declaration, or filing with,
or an exemption by, any Governmental Entity, or other third party, required to be obtained or made
by such party or its Subsidiaries in connection with this Agreement and consummating the
transactions contemplated hereby or the taking of any action contemplated by this Agreement.

     6.11 Estimated Lifetime Value. eHealth and HBDC agree that, after the execution of
this Agreement and prior to the Closing of the BOR Transfer with respect to any Carrier Book,
eHealth and HBDC shall attempt in good faith to agree upon the Estimated Lifetime Value of such
Carrier Book, subject to HBDC’s compliance with the provisions of this Agreement (including,
without limitation, by providing eHealth with any information eHealth reasonably requests relating
to such Estimated Lifetime Value) and to the relevant Specified Carrier’s provision of information
reasonably requested by eHealth.

     6.12 Additional Documents and Further Assurances. At any time or from time to time
after the Closing, at eHealth’s reasonable request and without any further consideration, HBDC
shall and shall cause its Subsidiaries to: (a) execute and deliver to eHealth such other
instruments of sale, transfer, conveyance, assignment and confirmation; (b) provide such materials
and information; and (c) take such other actions, as eHealth may reasonably deem necessary or
desirable in order more effectively to transfer, convey and assign to eHealth, to confirm eHealth’s
title to, all of the Transition Assets, to put eHealth in actual possession and operating control
of the Transition Assets, to assist eHealth in exercising all rights with respect thereto, to
ensure that eHealth receives commissions on the Transition Policies at the same rate and in the
same manner as such commissions were received prior to the date of this Agreement, and otherwise to
cause HBDC to fulfill its obligations under this Agreement and the Ancillary Agreements. Without
limiting the foregoing, HBDC agrees to maintain its books and records relating to the Transition
Policies and to provide eHealth with reasonable access thereto.

     6.13 HBDC Receipt of Commission Payments. It is the intent of the parties to effect
the BOR Transfer referenced in this Agreement such that eHealth shall receive all commission
payments made on or after February 1, 2009 for Transition Policies that are in force on or after
February 1, 2009 (the “Transition Commissions”). Accordingly, if HBDC receives any
Transition Commissions from any Specified Carrier, HBDC shall immediately notify eHealth and pay to
eHealth the full amount of such Transition Commission payment (without offset of any kind) and
shall provide all statements or other documents received from the Specified Carrier in connection
therewith. In accordance with Sections 3.2(b) and 3.4, eHealth will thereafter
remit to HBDC the Transition Commission Payments relating to such Transition Policies. If HBDC
receives any Transition Commissions from any Specified Carrier prior to the Closing of the BOR
Transfer with respect to such Specified Carrier’s Carrier Book, HBDC shall, in accordance with this
Section 6.13, pay to eHealth the full amount of such Transition Commissions at such
Closing, and eHealth shall thereafter remit to HBDC the appropriate Transition Commission
Payments in accordance with Sections 3.2(b) and 3.4.

-17-

 

     6.14 eHealth Receipt of Commission Payments. It is the intent of the parties to
effect the BOR Transfer referenced in this Agreement such that HBDC shall continue to receive all
commission payments made on or after February 1, 2009 for Excluded Policies that are in force on or
after February 1, 2009. Accordingly, if eHealth receives any commission payments for Excluded
Policies from any Specified Carrier, eHealth shall immediately notify HBDC and pay to HBDC the full
amount of such commission payment (without offset of any kind) for such Excluded Policies and shall
provide all statements or other documents received from the Specified Carrier in connection
therewith. If eHealth receives any commission payments for Excluded Policies from any Specified
Carrier prior to the Closing of the BOR Transfer with respect to such Specified Carrier’s Carrier
Book, eHealth shall, in accordance with this Section 6.14, pay to HBDC the full amount of
such commission payments for Excluded Policies at such Closing.

     6.15 Liens. HBDC covenants and agrees to satisfy when due all obligations of HBDC or
its Subsidiaries that have resulted or result in the imposition of any Lien on any of the
Transition Assets.

     6.16 Ancillary Agreements. Each of eHealth and HBDC shall execute and deliver the
Ancillary Agreements required to be executed by them.

ARTICLE VII

CONDITIONS TO THE CLOSING

     7.1 Conditions to Obligations of Each Party. The respective obligations of eHealth
and HBDC to effect the transactions contemplated hereby (including the Closing of each portion of
the BOR Transfer relating to a Specified Carrier’s Carrier Book) shall be subject to the
satisfaction, at or prior to the Closing, of the following conditions:

          (a) No Order. No Governmental Entity shall have enacted, issued, promulgated,
enforced or entered any statute, rule, regulation, executive order, decree, injunction or other
order (whether temporary, preliminary or permanent) which is in effect and which has the effect of
making the transactions contemplated hereby illegal or otherwise prohibiting the consummation of
the transactions contemplated hereby.

          (b) No Injunctions or Restraints; Illegality. No temporary restraining order,
preliminary or permanent injunction or other order issued by any court of competent jurisdiction or
other legal restraint or prohibition preventing the consummation of the transactions contemplated
hereby shall be in effect, nor shall any proceeding brought by a Governmental Entity be seeking any
of the foregoing be pending.

     7.2 Additional Conditions to the Obligations of eHealth. The obligation of eHealth to
effect the transactions contemplated hereby shall be subject to the satisfaction at or prior to a
Closing (including the Closing of each portion of the BOR Transfer relating to a Specified
Carrier’s Carrier Book) of each of the following conditions, any of which may be waived, in
writing, exclusively by eHealth:

-18-

 

          (a) Representations, Warranties and Covenants. (i) The representations and warranties
of the HBDC contained in this Agreement shall be true and correct, in each case on the date of this
Agreement and as of each Closing Date; and (ii) HBDC shall have performed and complied in all
material respects with all covenants and obligations under this Agreement required to be performed
or complied with by HBDC as of the Closing.

          (b) Governmental Approval. Approvals from any court, administrative agency,
commission or other federal, state, county or local deemed appropriate or necessary by eHealth
shall have been timely obtained.

          (c) Litigation. There shall be no Action or Proceeding of any nature pending or
threatened against (i) HBDC, its properties or any of its officers or directors arising out of, or
in any way connected with, the transactions contemplated by this Agreement or any Ancillary
Agreement; or (ii) HBDC, its properties or any of its officers or directors arising out of, or in
any way connected with, the Business or the Transition Assets that could reasonably be expected to
impair eHealth’s rights in the Transition Assets in any material respect, or (iii) the Business or
the Transition Assets that could reasonably be expected to impair eHealth’s rights in the
Transition Assets in any material respect.

          (d) Officer’s Certificate. eHealth shall have received a certificate (“Officer’s
Certificate”) validly executed by the Chief Financial Officer of HBDC for and on its behalf, to
the effect that, as of the Closing, each of the conditions set forth in this Section 7.2 
have been satisfied (unless otherwise waived by eHealth in accordance with the terms hereof) and
setting forth the amount of Transition Commissions received on any Transition Policies in the
Carrier Book that relate to the Closing.

          (e) Certificate of Secretary of HBDC. eHealth shall have received a certificate,
validly executed by the Secretary of HBDC, certifying as to the valid adoption of resolutions of
the Board of Directors of HBDC approving this Agreement and the consummation of the transactions
contemplated hereby.

          (f) BOR Transfer Letter. HBDC shall have delivered to the relevant Specified Carrier
(in such form as the Specified Carrier may request) a request to transfer BOR status to eHealth.

          (g) Specified Carrier Consents. eHealth shall have received all consents, approvals
and agreements as eHealth deems necessary or appropriate in connection with the portion of the BOR
Transfer that is the subject of the Closing.

          (h) Financing. eHealth shall have received from HBDC written confirmation and/or
documents reasonably satisfactory to eHealth demonstrating that HBDC has closed its most recent
round of financing and that HBDC has sufficient cash to operate its business for at least six (6)
months after the final Closing Date.

          (i) Third Party Consents. eHealth shall have received all other consents, waivers,
approvals, Lien releases, licenses and assignments required in connection with the execution and
delivery of this Agreement or any Ancillary Agreement, or to consummate the transactions
contemplated hereby or thereby to eHealth’s satisfaction.

-19-

 

          (j) Reserved; Not used.

          (k) Estimated Lifetime Value. eHealth and HBDC shall have agreed upon the Estimated
Lifetime Value of the Carrier Book that is the subject of the Closing and such agreement shall be
evidenced in a writing executed by each of eHealth and HBDC.

          (l) Certifications of HBDC. eHealth shall have received such certifications and other
documents in connection with the Closing of the transactions contemplated by this Agreement as
eHealth shall reasonably request.

          (m) Deliveries. HBDC shall have delivered to eHealth executed copies of the Ancillary
Agreements and a completed Form W-9 and shall have delivered, transferred or assigned (as the case
may be) all of the Transition Assets related to the BOR Transfer that is the subject of the
Closing.

          (n) Lead Database. HBDC shall have (i) delivered to eHealth the Lead Database in such
manner as eHealth shall reasonably request; and (ii) implemented the links as set forth in the
Marketing and Referral Agreement.

          (o) Excess GRIC Liability. As a condition to the Closing of the portion of the BOR
Transfer relating to GRIC Transition Policies, the Excess GRIC Liability shall have been paid and
eHealth and HBDC both shall have received evidence reasonably satisfactory to both eHealth and HBDC
of such payment.

     7.3 Conditions to Obligations of HBDC. The obligations of HBDC to consummate and
effect the transactions contemplated hereby (including the Closing of each portion of the BOR
Transfer relating to a Specified Carrier’s Carrier Book) shall be subject to the satisfaction at or
prior to the Closing of each of the following conditions, any of which may be waived, in writing,
exclusively by HBDC:

          (a) Representations, Warranties and Covenants. (i) The representations and warranties
of eHealth contained in this Agreement shall be true and correct in each case on the date of this
Agreement and as of each Closing Date; and (ii) eHealth shall have performed and complied in all
material respects with all covenants and obligations under this Agreement required to be performed
or complied with by eHealth as of the Closing.

          (b) Deliveries. eHealth shall have delivered to HBDC executed copies of each
Ancillary Agreement required to be executed by it.

          (c) Specified Carrier Consents. HBDC shall have received all Specified Carrier
consents, approvals and agreements necessary to effect the BOR Transfer that is the subject of the
Closing.

          (d) Estimated Lifetime Value. eHealth and HBDC shall have agreed upon the Estimated
Lifetime Value of the Carrier Book that is the subject of the Closing and such agreement shall be
evidenced in a writing executed by each of eHealth and HBDC.

-20-

 

          (e) Referral Website. eHealth shall have implemented the referral website described
in the Marketing and Referral Agreement.

ARTICLE VIII

SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION

     8.1 Survival of Representations and Warranties. The representations and warranties of
HBDC contained in this Agreement or in any certificate or other instrument delivered pursuant to
this Agreement, shall survive the Closing hereunder.

     8.2 Indemnification. 

          (a) HBDC Indemnification. HBDC hereby agrees to indemnify and hold eHealth and
eHealth, Inc. (eHealth’s parent corporation), and each of their stockholders, officers, directors,
employees, agents, attorneys, representatives and affiliates (collectively, the “Purchaser
Indemnified Parties”), harmless against all claims, losses, liabilities, damages, deficiencies,
costs and expenses, including reasonable attorneys’ fees and expenses of investigation and defense
(hereinafter individually a “Loss” and collectively “Losses”), incurred or
sustained by such Persons, directly or indirectly, as a result of (i) any breach or inaccuracy of a
representation or warranty of HBDC contained in this Agreement, the Ancillary Agreements, or in any
certificate, instrument, or other document delivered by HBDC pursuant to this Agreement (without
giving effect to any limitation as to “materiality,” “material adverse effect,” or similar
qualifications set forth therein); (ii) any failure by HBDC to perform or comply with any covenant
applicable to it contained in this Agreement or the Ancillary Agreements; and (iii) any Excluded
Liability.

          (b) eHealth Indemnification. eHealth hereby agrees to indemnify and hold HBDC, and
each of HBDC’s stockholders, officers, directors, employees, agents, attorneys, representatives and
affiliates (collectively, the “HBDC Indemnified Parties”), harmless against all Losses,
incurred or sustained by such Persons, directly or indirectly, as a result of (i) any breach or
inaccuracy of a representation or warranty of eHealth contained in this Agreement or in any
certificate, instrument, or other document delivered by eHealth pursuant to this Agreement (without
giving effect to any limitation as to “materiality,” “material adverse effect,” or similar
qualifications set forth therein); (ii) any failure by eHealth to perform or comply with any
covenant applicable to it contained in this Agreement and to be performed by eHealth after the
Closing.

     8.3 Indemnification Procedure. Any Person seeking indemnification pursuant to this
Article VIII (the “Indemnified Party”) shall give notice of an Indemnification Claim (as
defined below) by delivery of an Indemnification Certificate (as defined in the immediately
succeeding sentence) to the party from whom indemnification is sought (the “Indemnifying
Party”). For purposes hereof, “Indemnification Certificate” shall mean a certificate
signed by any officer or duly authorized representative of an Indemnified Party (i) stating that
the Indemnified Party has paid, sustained, incurred, or properly accrued, or reasonably anticipates
that it will have to pay, sustain, incur, or accrue Losses, and (ii) specifying in reasonable
detail the individual items of Losses included in the amount so stated, the date each such item was
paid, sustained, incurred or properly accrued, or the basis for such anticipated liability, and the
nature of the indemnification claim

-21-

 

hereunder. The Indemnifying Party may object to any Indemnification Claim set forth in an Indemnification
Certificate by delivery to the Indemnified Party of a written statement of objection (an
“Indemnification Objection Notice”) within twenty (20) calendar days’ of receipt of an
Indemnification Certificate. “Indemnification Claim” shall mean any matter which an
Indemnified Party has determined has given rise to a right of indemnification under this Agreement.

     8.4 Resolution of Conflicts; Arbitration. 

          (a) If an Indemnifying Party delivers an Indemnification Objection Notice to the Indemnified
Party in accordance with Section 8.3, the Indemnifying Party and the Indemnified Party
shall meet in good faith to attempt to agree upon the rights of the respective parties with respect
to each Indemnification Claim. If the Indemnifying Party and the Indemnified Party should so
agree, a memorandum setting forth such agreement shall be prepared and signed by both parties.

          (b) If no such agreement can be reached after good faith negotiation and prior to forty-five
(45) calendar days after delivery of an Indemnification Objection Notice, either the Indemnifying
Party or the Indemnified Party may demand arbitration of the matter unless the amount of the Loss
that is at issue is the subject of pending litigation with respect to a Third Party Claim (as
defined below), in which event arbitration shall not be commenced until such amount is ascertained
or both parties agree to arbitration, and in either such event the matter shall be settled by
arbitration conducted by one arbitrator mutually agreeable to the Indemnifying Party and the
Indemnified Party. In the event that, within thirty (30) calendar days after submission of any
dispute to arbitration, the Indemnifying Party and the Indemnified Party cannot mutually agree on
one arbitrator, then, within fifteen (15) calendar days after the end of such thirty (30) calendar
day period, the Indemnifying Party and the Indemnified Party shall each select one arbitrator. The
two arbitrators so selected shall select the arbitrator.

          (c) Any such arbitration shall be held in Santa Clara County, California, under the rules then
in effect of the American Arbitration Association. The arbitrator shall determine how all expenses
relating to the arbitration shall be paid, including without limitation, the respective expenses of
each party, the fees of the arbitrator and the administrative fee of the American Arbitration
Association. The arbitrator shall set a limited time period and establish procedures designed to
reduce the cost and time for discovery while allowing the parties an opportunity, adequate in the
sole judgment of the arbitrator to discover relevant information from the opposing parties about
the subject matter of the dispute. The arbitrator shall rule upon motions to compel or limit
discovery and shall have the authority to impose sanctions, including attorneys’ fees and costs, to
the same extent as a competent court of law or equity, should the arbitrator determine that
discovery was sought without substantial justification or that discovery was refused or objected to
without substantial justification. The decision of the arbitrator as to the validity and amount of
any Indemnification Claim in such Indemnification Certificate shall be final, binding, and
conclusive upon the Indemnifying Party and the Indemnified Party. Such decision shall be written
and shall be supported by written findings of fact and conclusions that shall set forth the award,
judgment, decree or order awarded by the arbitrator. Judgment upon any award rendered by the
arbitrator may be entered in any court having jurisdiction. The foregoing arbitration provision
shall apply to any dispute between an Indemnifying Party and any Indemnified Party pursuant to this
Article VIII.

-22-

 

     8.5 Third Party Claims. In the event an Indemnified Party becomes aware of a
third-party claim which such Indemnified Party reasonably believes may result in a demand for
indemnification pursuant to this Article VIII (a “Third Party Claim”), the
Indemnified Party shall notify the Indemnifying Party of such claim, and the Indemnifying Party
shall be entitled, at its expense, to participate in, but not to determine or conduct, the defense
of such claim. The Indemnified Party shall have the right, in its sole discretion, to conduct the
defense of and settle any such Third Party Claim; provided, however, that except with the consent
of the Indemnifying Party, no settlement of any such Third Party Claim shall alone be determinative
of the amount of Losses relating to such matter. In the event that the Indemnifying Party has
consented to any such settlement, the Indemnifying Party shall have no power or authority to object
under any provision of this Article VIII to the amount of any claim by the Indemnified
Party against the Indemnifying Party with respect to such settlement.

     8.6 Payment of Indemnification. In the event that (a) an Indemnifying Party shall not
have timely objected to the amount claimed by an Indemnified Party for indemnification with respect
to any Loss in accordance with the procedures set forth in Section 8.3, or (b) an
Indemnifying Party shall have delivered an Indemnification Objection Notice as to the amount of any
indemnification requested by an Indemnified Party and either (i) the Indemnifying Party and the
Indemnified Party shall have, subsequent to the giving of such notice, mutually agreed that the
Indemnifying Party is obligated to indemnify the Indemnified Party for a specified amount, (ii) a
final award shall have been rendered in an arbitration pursuant to Section 8.4, or (iii) a
final nonappealable judgment shall have been rendered by the court having jurisdiction over the
matters relating to such Indemnification Claim by an Indemnified Party for indemnification from an
Indemnifying Party, then the Indemnifying Party shall pay any such indemnification owed to the
Indemnified Party within fifteen (15) calendar days of such mutual agreement or final nonappealable
judgment, as applicable, by wire transfer in immediately available funds to an account directed by
the Indemnified Party.

     8.7 Remedy. To the extent that an Indemnified Party may recover for Losses pursuant
to Section 8.2, such Indemnified Party agrees to take commercially reasonable steps to
avoid and mitigate such Losses. In addition the amount of any claim for Losses shall be net of any
amount actually recovered by an Indemnified Party pursuant to any insurance policy, provided,
however, that the Indemnifying Party shall not be obligated to seek such recovery. HBDC and
eHealth acknowledge that, except in the event of fraud, intentional misrepresentation or willful
misconduct, the provisions of this Article VIII shall be their sole and exclusive remedy
from and after the Closing for any claims arising under this Agreement; provided, however, the
foregoing clause of this sentence shall not be deemed a waiver by eHealth of any right to specific
performance or injunctive relief.

ARTICLE IX

TERMINATION, AMENDMENT AND WAIVER

     9.1 Termination. Except as provided in Section 9.2, this Agreement may be
terminated and the transactions contemplated hereby abandoned at any time prior to the first
Closing hereunder:

          (a) By the mutual written agreement of the parties;

-23-

 

          (b) By either eHealth or HBDC, if (i) the first Closing has not occurred by March 15, 2009;
provided, however, that the right to terminate this Agreement under this
Section 9.1(b)(i) shall not be available to any party whose willful failure to fulfill any
obligation hereunder or other breach of this Agreement has been the cause of, or resulted in, the
failure of the Closing to occur on or before such date; (ii) there shall be in effect a final
nonappealable order of a federal or state court preventing consummation of the transactions
contemplated hereby; or (iii) there shall be any legal requirement enacted, promulgated or issued
or deemed applicable to the transactions contemplated hereby by any Governmental Entity that would
make consummation of the transactions contemplated hereby illegal;

          (c) By eHealth, if eHealth is not in material breach of its obligations under this Agreement
and there has been a breach of any representation, warranty, covenant or agreement contained in
this Agreement on the part of HBDC and (i) HBDC is not using its commercially reasonable efforts to
cure such breach, or has not cured such breach within 15 days, after notice of such breach has been
given by eHealth to HBDC in accordance with Section 10.1; provided,
however, that, no cure period shall be required for any such breach which by its nature
cannot be cured and (ii) as a result of such breach, one or more of the conditions set forth in
Section 7.1 or Section 7.2 would not be satisfied at or prior to the Closing;

          (d) By HBDC, if it is not in material breach of its obligations under this Agreement and there
has been a breach of any representation, warranty, covenant or agreement contained in this
Agreement on the part of eHealth and (i) eHealth is not using its commercially reasonable efforts
to cure such breach, or has not cured such breach within 15 days, after notice of such breach has
been given by HBDC to eHealth in accordance with Section 10.1; provided,
however, that, no cure period shall be required for any such breach which by its nature
cannot be cured and (ii) as a result of such breach, one or more of the conditions set forth in
Section 7.1 or Section 7.3 would not be satisfied at or prior to the Closing; or

     9.2 Effect of Termination. In the event of termination of this Agreement as provided
in Section 9.1, this Agreement shall forthwith become void and there shall be no liability
or obligation on the part of any party hereto, or its affiliates, officers, directors or
stockholders; provided that each party shall remain liable for any willful breaches of this
Agreement prior to its termination; and provided further that, the provisions of Section
6.4 (confidentiality), Section 6.7 (public disclosure), Article X and this
Section 9.2 of this Agreement shall remain in full force and effect and survive any
termination of this Agreement. Notwithstanding the foregoing, nothing contained herein shall
relieve any party from liability for any willful breach hereof.

     9.3 Amendment. This Agreement may be amended by the parties hereto at any time by
execution of an instrument in writing signed on behalf of each of the parties hereto.

     9.4 Extension; Waiver. At any time prior to the Closing, eHealth, on the one hand,
and HBDC, on the other hand, may, to the extent legally allowed, (a) extend the time for the
performance of any of the obligations of the other party hereto, (b) waive any inaccuracies in the
representations and warranties made to such party contained herein or in any document delivered
pursuant hereto and (c) waive compliance with any of the agreements or conditions for the benefit
of such party contained herein. Any agreement on the part of a party hereto to any such extension
or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such
party.

-24-

 

ARTICLE X

GENERAL PROVISIONS

     10.1 Notices. All notices and other communications hereunder shall be in writing and
shall be deemed given upon receipt if delivered personally or by commercial delivery service, or
upon receipt or refusal of delivery if mailed by registered or certified mail (return receipt
requested) or sent via facsimile (with acknowledgment of complete transmission from the recipient
of such facsimile) to the parties at the following addresses (or at such other address for a party
as shall be specified by like notice):

          (a) if to eHealth, to:

eHealthInsurance Services, Inc.

440 East Middlefield Road

Mountain View, California 94043

Attention: Bruce Telkamp, Executive Vice President

Telephone No.: 650.210.3131

Facsimile No.: 650.961.2141

          (b) if to HBDC, to:

Health Benefits Direct Corporation

Radnor Financial Center

150 North Radnor Chester Road, Suite B101

Radnor, PA 19087

Attn: Anthony R. Verdi, Chief Financial Officer

Telephone No.: 484.654.2206

Facsimile No.: 484.654.2212

and also under separate cover to

Health Benefits Direct Corporation

Radnor Financial Center

150 North Radnor Chester Road, Suite B101

Radnor, PA 19087

Attn: Francis L. Gillian III, Vice President / Controller

Telephone No.: 484.654.2203

Facsimile No.: 484.654.2209

     10.2 Expenses. All fees and expenses incurred in connection with this Agreement
including, without limitation, all legal, accounting, financial advisory, consulting and all other
fees and expenses of third parties (including without limitation brokerage or finders’ fees,
agents’ commissions or any similar charges) incurred by a party hereto, in connection with the
negotiation and effectuation of the terms and conditions of this Agreement and the transactions
contemplated hereby, shall be the obligation of the respective party incurring such fees and
expenses.

-25-

 

     10.3 Right of Offset. eHealth shall have the right to offset against amounts owed to
HBDC pursuant to this Agreement or any Ancillary Agreement, any amount owed by HBDC to eHealth
pursuant to the terms of this Agreement or an Ancillary Agreement.

     10.4 Entire Agreement; Assignment. This Agreement and Schedules hereto, the Ancillary
Agreements, the HBDC Disclosure Schedule, the NDA, the Confidentiality Agreement and the documents
and instruments and other agreements among the parties hereto referenced herein: (a) constitute the
entire agreement among the parties with respect to the subject matter hereof and thereof and
supersede all prior agreements and understandings both written and oral, among the parties with
respect to the subject matter hereof and thereof; and (b) are not intended to confer upon any other
person any rights or remedies hereunder. This Agreement shall not be assigned by operation of law
or otherwise without the written consent of the other party hereto. Notwithstanding the foregoing,
(i) eHealth may, without written consent, assign all of the rights and obligations under this
Agreement in connection with any sale of eHealth whether by means of an asset sale, stock sale or
merger; and (ii) after all Closings hereunder, HBDC may, without written consent, assign all of the
rights and obligations under this Agreement in connection with the sale of HBDC.

     10.5 Severability. In the event that any provision of this Agreement or the
application thereof, becomes or is declared by a court of competent jurisdiction to be illegal,
void or unenforceable, the remainder of this Agreement will continue in full force and effect and
the application of such provision to other persons or circumstances will be interpreted so as
reasonably to effect the intent of the parties hereto. The parties further agree to replace such
void or unenforceable provision of this Agreement with a valid and enforceable provision that will
achieve, to the extent possible, the economic, business and other purposes of such void or
unenforceable provision.

     10.6 Governing Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of California, regardless of the laws that might otherwise
govern under applicable principles of conflicts of laws thereof.

     10.7 No Third Party Beneficiaries. This Agreement shall not confer any rights or
remedies upon any person or entity other than the parties hereto and their respective successors
and permitted assigns.

     10.8 Specific Performance. The parties hereto agree that irreparable damage will
occur in the event that any of the provisions of this Agreement are not performed in accordance
with their specific terms or are otherwise breached. It is accordingly agreed that the parties
shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to
enforce specifically the terms and provisions hereof in any court of the United States or any state
having jurisdiction, this being in addition to any other remedy to which they are entitled at law
or in equity.

     10.9 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL
RIGHT TO TRIAL BY JURY AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT
OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN
NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

-26-

 

     10.10 Counterparts. This Agreement may be executed in one or more counterparts, all
of which shall be considered one and the same agreement and shall become effective when one or more
counterparts have been signed by each of the parties and delivered to the other party, it being
understood that all parties need not sign the same counterpart. This Agreement may be executed and
delivered by facsimile or electronic transmission.

*****

-27-

 

     IN WITNESS WHEREOF, eHealth and HBDC have caused this Client Transition Agreement to be signed
as of the date first written above.

	 	 	 	 	 
	“EHEALTH” 	EHEALTHINSURANCE SERVICES, INC.

a Delaware corporation

 	 
	 	By:  	 	 
	 	 	   
                    
   ,          
           	 

“HBDC”

	 	 	 	 	 
	 	HEALTH BENEFITS DIRECT CORPORATION

a Delaware corporation

 	 
	 	By:  	 	 
	 	 	   
                    
   ,          
           	 
	 	 	 	 
	 
	 	HBDC II, INC.

a Delaware corporation

 	 
	 	By:  	 	 
	 	 	   
                    
   ,exv4w20

Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A
complete version of this exhibit has been filed separately with the Securities and Exchange
Commission.

License Agreement

Made as of the 2nd day of April 2008 (the “EFFECTIVE DATE”)

by and between

Chiesi Farmaceutici S.p.A.

a company duly organized and existing under the laws of Italy, with its principal place of business
at Via Palermo 26/A, 43100 Parma, Italy

(hereinafter referred to as “LICENSOR”)

and

Eurand Pharmaceuticals Inc.

a company duly organized and existing under the laws of Delaware, with its principal place of
business at 790 Township Line Road, Suite 250, Yardley, Pennsylvania 19067 U.S.A.

(hereinafter referred to as “LICENSEE”)

1

 

WITNESSETH

WHEREAS, LICENSOR has developed the LICENSED PRODUCT (hereinafter defined) containing the COMPOUND
(hereinafter defined) and LICENSOR owns or CONTROLS (hereinafter defined) the LICENSED KNOW HOW
(hereinafter defined) and LICENSED TRADEMARK (hereinafter defined), all of them relevant to the
LICENSED PRODUCT;

WHEREAS, LICENSEE has the capabilities, directly or indirectly, to develop, register, manufacture,
distribute, market and sell pharmaceutical specialties in the TERRITORY (as hereinafter defined);

WHEREAS, LICENSEE has reasonably investigated the LICENSED KNOW HOW;

WHEREAS, LICENSEE after having reasonably investigated the LICENSED KNOW HOW, desires to acquire a
license to further develop the LICENSED PRODUCT and to manufacture, use, market, promote, sell and
distribute the LICENSED PRODUCT under a LICENSED TRADEMARK in the LICENSED FIELD (hereinafter
defined) in the TERRITORY, and LICENSOR is willing to provide LICENSEE with such license, subject
to the terms and conditions of this AGREEMENT;

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and
intending to be bound, and it being understood that the above recitals shall be deemed to be
incorporated into and form part of this AGREEMENT, the parties hereby agree as follows:

Article 1.00 — Definitions

For the purpose of this AGREEMENT the following definitions shall be applicable.

	1.01	 	“AFFILIATE” shall mean any company or business entity controlled by, controlling or under
common control with a party to this AGREEMENT. For this purpose, “control” shall mean the
power, directly or indirectly, to direct or cause the direction of the management and policies
of a company and control is conclusively presumed in

2

 

	 	 	case of direct or indirect ownership of more than 50% (fifty percent) of the voting stock of
such company.

	1.02	 	“AGREEMENT” shall mean this License Agreement by and between LICENSOR and LICENSEE together
with all its Appendices.

	1.03	 	“COMPOUND” shall mean the active ingredient known as “Beclomethasone dipropionate”.

	1.04	 	“CONTROLLED” or “TO CONTROL” shall in relation to any INTELLECTUAL PROPERTY RIGHTS mean such
INTELLECTUAL PROPERTY RIGHTS in the possession (whether by ownership, licence or other right,
other than pursuant to this AGREEMENT) by a party or its AFFILIATES with the ability to grant
to the other party access and/or a licence (or sublicence) as provided herein under such right
without violating the terms of any agreement or other arrangement with any THIRD PARTY and
without requiring any further consent from such THIRD PARTY.

	1.05	 	“DEVELOPMENT PLAN” shall mean a detailed development plan, including study protocols,
timelines and associated budget, *** relating to the further development of the LICENSED
PRODUCT in accordance with the terms of this AGREEMENT. A first outline of the DEVELOPMENT
PLAN, as agreed upon between the parties, shall be attached hereto as Appendix A *** below,
which shall be considered an integral part of this AGREEMENT.

	1.06	 	“FIRST COMMERCIAL SALE” shall mean the first sale of the LICENSED PRODUCT in each country of
the TERRITORY by LICENSEE, directly or indirectly, to an unrelated THIRD PARTY on a commercial
basis.

	1.07	 	“FDA” shall mean the United States Food and Drug Administration or any successor entity
thereto.

	1.08	 	“HPB” shall mean the Health Protection Branch in Canada or any successor entity thereto.

3

 

	1.09	 	“IMPROVEMENT” shall mean any discovery, development, invention, enhancement or modification,
patentable or otherwise, relating to the LICENSED PRODUCT owned or CONTROLLED by LICENSOR or
LICENSEE, including any analytical methodology, ingredients, preparation, presentation, means
of delivery or administration, indication, use or packaging of the LICENSED PRODUCT.

	1.10	 	“IND” shall mean an Investigational New Drug Application in respect of the LICENSED PRODUCT
in the TERRITORY.

	1.11	 	“INTELLECTUAL PROPERTY RIGHTS” shall mean patents, trade marks, service marks, logos, trade
names, rights in designs, copyright, utility models, rights in know how and other intellectual
property rights, in each case whether registered or unregistered and including applications
for registration, and all rights or forms of protection having equivalent or similar effect
anywhere in the world.

	1.12	 	“LICENSED FIELD” shall mean the treatment of inflammatory bowel diseases and related
complications.

	1.13	 	“LICENSED KNOW HOW” shall mean, in relation to the LICENSED PRODUCT, all information,
procedures (including, but not limited to manufacturing and packaging), instructions,
techniques, data, technical information, knowledge and experience (including toxicological,
pharmaceutical, clinical, non-clinical, medical data and health registration data), designs,
manufacturing processing, processing specifications and technology to the extent necessary,
useful or used to develop, make, package, market, promote, distribute, sell, or offer for sale
the LICENSED PRODUCT in the TERRITORY, whether in written electronic or other form, in each
case as owned or CONTROLLED by LICENSOR as of the EFFECTIVE DATE or during the TERM.

	1.14	 	“LICENSED PRODUCT” shall mean the finished, i.e. formulated and packaged ready for use on
human patients, pharmaceutical product containing the

4

 

	 	 	COMPOUND as the pharmaceutically active ingredient, in a tablet form, manufactured under the
LICENSED KNOW HOW.

	1.15	 	“LICENSED TECHNOLOGY” shall mean the LICENSED KNOW HOW, the LICENSED TRADEMARK and any
IMPROVEMENTS CONTROLLED by LICENSOR.

	1.16	 	“LICENSED TRADEMARK” shall mean the trademark belonging to or CONTROLLED by LICENSOR, which
shall be used by LICENSEE to market and sell the LICENSED PRODUCT in the TERRITORY and which
is set out in Appendix B, which shall be considered an integral part of this AGREEMENT.

	1.17	 	“MARKETING EXCLUSIVITY PERIOD” shall mean that period of regulatory exclusivity conveyed by
the FDA and the HPB for the first LICENSED PRODUCT to achieve an NDA and an NDS, respectively.

	1.18	 	“NDA” shall mean a New Drug Application approved by the FDA, and any renewals, amendments or
supplements thereto in respect of the LICENSED PRODUCT.

	1.19	 	“NDS” shall mean a New Drug Submission approved by the HPB, and any renewals, amendments or
supplements thereto in respect of the LICENSED PRODUCT.

	1.20	 	“NET SALES” shall ***

	1.21	 	“PATENT” or “PATENTS” shall mean any and all patent(s) and patent applications owned or
CONTROLLED as of the EFFECTIVE DATE or during the TERM by LICENSOR as well as any extension
thereof, including supplementary protection certificates, together with any continuations,
continuations-in-part, divisions and reissues thereof, in each case which if not licensed
herein would be infringed by using, developing, manufacturing, packaging, registering,
storing, handling, promoting, distributing, marketing, selling or otherwise transferring
physical possession of or otherwise transferring title in or to the LICENSED PRODUCT.

5

 

	1.22	 	“TERRITORY” shall mean the United States of America (including the US Virgin Islands and
Puerto Rico) and Canada.

	1.23	 	“THIRD PARTY” shall mean any entity other than LICENSOR, LICENSEE and their respective
AFFILIATES.

Article 2.00 — Grant

2.01

LICENSOR hereby grants to LICENSEE, subject to the terms and conditions herein contained, and
LICENSEE hereby accepts from LICENSOR, (a) a non-exclusive license outside the TERRITORY, under the
LICENSED TECHNOLOGY, to use, develop, make and have made (including, manufacturing and packaging),
store and handle, the LICENSED PRODUCT and IMPROVEMENTS (owned or CONTROLLED by LICENSOR) in the
LICENSED FIELD but solely for subsequent export thereof in the TERRITORY for resale, and (b) an
exclusive (even as to LICENSOR) non-transferable license (including the right to grant sub-licenses
in the limits set forth under Section 2.02 below) in the TERRITORY, under the LICENSED TECHNOLOGY,
to use, develop, make and have made (including, manufacturing and packaging), register, import,
store, handle, market, promote, distribute, sell and/or offer for sale, the LICENSED PRODUCT and
IMPROVEMENTS (owned or CONTROLLED by LICENSOR) in the LICENSED FIELD. For purposes of clarity, the
above license grants include the ability to subcontract to THIRD PARTIES the above allowed
activities of using, developing, making and having made (including, manufacturing and packaging),
storing and handling and the engagement of a contract sales force for the marketing and sale of the
LICENSED PRODUCT in the TERRITORY.
Furthermore, the license granted in paragraph (a) above also includes a non exclusive unblocking
license under any PATENT to the extent strictly necessary to LICENSEE to perform the activities as
set out in such paragraph (a).

2.02

Except to its AFFILIATES or to THIRD PARTIES as specifically set forth under Section 2.01 above,
LICENSEE ***.

6

 

2.03

Except to the extent permitted under this AGREEMENT, ***
***
Without prejudice to the foregoing, in the event that LICENSOR decides to license the LICENSED
PRODUCT in the TERRITORY for use in the Gastrointestinal field, then LICENSEE ***

2.04

All rights and licenses granted to LICENSEE under this Article 2.00 are, and shall be deemed to be,
for purposes of applicable bankruptcy law (including section 365(n) of the United States Bankruptcy
Code), licenses of rights to “intellectual property” (including as such term is defined under
section 101(35A) of the United States Bankruptcy Code).

Article 3.00 — Milestone Payments 

3.01

In consideration of the rights granted to LICENSEE under this AGREEMENT, LICENSEE shall make to
LICENSOR total milestone payments of USD *** United States Dollars) made up as follows:

A. USD *** United States Dollars) ***;

B. USD *** United States Dollars) ***;

C. USD *** United States Dollars) ***;

D. USD *** United States Dollars) ***.

3.02

All milestone payments to be made by LICENSEE to LICENSOR under this Article 3.00 shall be ***.

7

 

Article 4.00 — Development and Regulatory Activities

4.01

Promptly after the EFFECTIVE DATE, LICENSOR shall disclose and transfer to LICENSEE, at its own
expense, all existing LICENSED KNOW HOW, including, without limitation the documents set forth on
Appendix C and, promptly thereafter, throughout the TERM disclose and transfer all LICENSED KNOW
HOW that LICENSOR shall CONTROL not previously disclosed and transferred to LICENSEE. In addition
and in order to support LICENSEE in carrying out the DEVELOPMENT PLAN, LICENSOR shall collaborate
with LICENSEE, for maximum 3 (three) meetings of 1 (one) day each at times and locations to be
agreed upon, for the time necessary to file an IND in the TERRITORY. Any further reasonable
assistance possibly required by LICENSEE from time to time for the above purposes may be furnished
by LICENSOR at reasonable terms to be agreed upon in due course.

4.02

LICENSEE shall use all commercially reasonable efforts (commensurate with those efforts used by
LICENSEE in connection with its own products of similar nature, value and status) (“ALL
COMMERCIALLY REASONABLE EFFORTS”) to ***.

4.03

LICENSEE undertakes to keep LICENSOR duly and fully informed of the activities made by LICENSEE
pursuant to Section 4.02 herein above by providing LICENSOR on an annual basis with detailed
reports in writing informing LICENSOR of the progress made and results of the studies undertaken
pursuant to the DEVELOPMENT PLAN. Furthermore, LICENSEE shall ***.
Finally, it is also agreed that the parties shall meet on a regular schedule (at least twice every
year) at a location mutually agreed, to review the progress of the development hereunder and to
discuss possible issues emerging from such development.

4.04

LICENSEE shall use ALL COMMERCIALLY REASONABLE EFFORTS to obtain, at its own costs, approval of an
NDA and an NDS and thereafter, LICENSEE shall undertake

8

 

all commercially reasonable steps to maintain the NDA and the NDS throughout the TERM, including
but not limited to any renewals thereof and any necessary submissions of information concerning the
efficacy and safety of the LICENSED PRODUCT.

LICENSEE shall provide LICENSOR, without unreasonable delay, with a full copy in electronic form of
the NDA and the NDS, any renewals thereof, any and all relevant communications with the FDA and the
HPB and/or comparable foreign authority concerning the NDA and the NDS; provided that such NDA, NDS
and any other documentation provided hereunder are the confidential information of LICENSEE
(subject to Section 11.02 below) and such copy shall not be reproduced or copied and shall be kept
in the legal archival files of LICENSOR and furthermore shall not be used for any purpose (except
as allowed under Article 5 hereunder) or disclosed to any THIRD PARTY without the prior written
consent of LICENSEE, unless the provisions of Section 12.06 below shall apply.

4.05

No later than 10 (ten) weeks after execution of this AGREEMENT, the parties shall promptly develop
and agree appropriate procedures for exchange of adverse event and pregnancy exposure data
concerning the LICENSED PRODUCT (the “PHARMACOVIGILANCE AGREEMENT”). Until the PHARMACOVIGILANCE
AGREEMENT is agreed, the parties shall exchange such data in a manner that enables each party to
fulfil regulatory requirements within their own territories (and within any other limits of this
AGREEMENT).

Article 5.00 — Grant Back 

5.01

Each party shall promptly disclose to the other party material, information and data that solely
results from its pharmacological and/or clinical and/or other investigations of the LICENSED
PRODUCT and any IMPROVEMENT to the LICENSED PRODUCT and/or its manufacture it develops or obtains
or it otherwise CONTROLS during the TERM, provided that such material, information, data and
IMPROVEMENTS provided hereunder are the confidential information of the party providing such to the
other party (subject to Article 11 below) and such items shall not be used or disclosed to any
THIRD PARTY without the prior written consent of the disclosing party except as specifically
allowed hereunder. Upon

9

 

the written request of LICENSOR, LICENSEE shall hereby grant LICENSOR a *** license, *** to use,
solely in relation to the LICENSED PRODUCT, all such material, information, data and IMPROVEMENTS
in the LICENSED FIELD outside the TERRITORY solely in countries where LICENSOR has a direct
marketing organization on the date of the above LICENSOR’s written request; furthermore, upon the
written request of LICENSOR, LICENSEE shall hereby grant LICENSOR such license for all other
countries outside the TERRITORY upon payment by LICENSOR to LICENSEE of royalties equal to ***
percent) on net sales (defined as the NET SALES hereunder) of LICENSED PRODUCT in such other
countries on the same terms as those applicable to the payment of royalties by LICENSEE hereunder.
LICENSOR shall pay the above royalties until such time as LICENSOR has paid to LICENSEE an amount
equal to *** percent) of the duly documented direct costs incurred by LICENSEE (with an audit right
for LICENSOR pursuant to the terms of Section 7.04 below) for generating the above material,
information, data and IMPROVEMENTS.

Article 6.00 — Marketing of LICENSED PRODUCT

6.01

LICENSEE undertakes to use ALL COMMERCIALLY REASONABLE EFFORTS to make the FIRST COMMERCIAL SALE in
the United States within *** from the date of obtaining the NDA. If LICENSEE, through no fault of
LICENSOR or otherwise due to applicable laws or factors beyond its reasonable control, fails to so
launch the LICENSED PRODUCT within such period, LICENSOR may terminate this AGREEMENT in the United
States upon *** written notice to LICENSEE, provided, however, that if LICENSEE makes the FIRST
COMMERCIAL SALE within said *** period, then this AGREEMENT shall continue in full force and
effect; further provided, that in the event that LICENSEE has a good faith belief that it can
effect a FIRST COMMERCIAL SALE but requires a commercially reasonable extension of the requisite
timelines, the parties shall make good faith efforts to meet and discuss such extension.

6.02

10

 

LICENSEE shall use ALL COMMERCIALLY REASONABLE EFFORTS to promote, market, create a demand and
continuously develop the sales of the LICENSED PRODUCT in the TERRITORY throughout the TERM.
Specifically, LICENSEE covenants that it will use ALL COMMERCIALLY REASONABLE EFFORTS to develop
and maintain sales and marketing staff sufficient for the coverage of the selected target
(physicians, non-physician prescribers, managed care organizations, pharmacies and wholesalers),
including a minimum number of medical contacts per calendar year and top ranking position in the
detailing list. LICENSEE, in promoting and marketing the LICENSED PRODUCT hereunder, covenants to
comply with any and all applicable laws in the TERRITORY.

6.03

LICENSEE shall submit to LICENSOR from time to time, but not less frequently than every ***, a
report on the market situation in the TERRITORY.

Article 7.00 — Royalties and Sales Reports

7.01

In further consideration of the rights granted to LICENSEE under Section 2.01 herein above,
LICENSEE shall pay to LICENSOR, in addition to the milestone payments referred to in Article 3.00
herein above, (a) for the period until the expiry of the MARKETING EXCLUSIVITY PERIOD in a country
in the TERRITORY royalties at the rate of *** percent) up to USD *** United States Dollars) of NET
SALES in such country in the TERRITORY and *** percent) above USD *** United States Dollars) of NET
SALES in a country in the TERRITORY and (b) following the period described in (a) above royalties
at the rate of *** percent) of NET SALES in such country in the TERRITORY, during the TERM as
defined in Section 12.01 below. Notwithstanding the above, in the event that LICENSEE determines
that it must procure and maintain a THIRD PARTY license in order to use, develop, make and have
made (including, manufacturing and packaging), register, store, handle, market, promote,
distribute, sell and/or offer for sale the LICENSED PRODUCT and it is necessary for LICENSEE to
make royalty payments and/or other payments to such THIRD PARTY to secure such license
(collectively, the “THIRD PARTY PAYMENTS”), LICENSEE will be entitled to offset all such THIRD
PARTY

11

 

PAYMENTS against up to *** percent) of any royalties owed to LICENSOR pursuant to this Section 7.01
during the TERM.

7.02

LICENSEE shall provide LICENSOR within *** after the end of each calendar quarter, with a report,
divided into one-month periods, stating the volume of LICENSED PRODUCT distributed free of charge,
gross sales in units and values and deductions therefrom in computing NET SALES and the amount of
royalties accrued in such quarter. The amount of royalties accrued for sales within Canada shall be
stated in the local currency for Canada and converted into USD$ for each month in such calendar
quarter on the basis of the average of the daily closing official exchange rate(s) within such
months quoted in the London Financial Times or any successor publication. ***, LICENSEE shall
transfer, by wire, the due amount of royalties to such bank account as LICENSOR may indicate from
time to time. Payment of all royalties due hereunder shall be made in USD$.

7.03

In the event that any payment due hereunder is not made when due, the payment shall accrue
interest, beginning on the first day following the calendar quarter to which such payment relates,
calculated at the annual rate of the sum of (a) ***percent), plus (b) the yield rate of the US 10
Year Treasury Note as quoted in the London Financial Times or any successor publication on the date
said payment is due, or on the date the payment is made, whichever is higher, the interest being
compounded on the last day of each calendar quarter, provided that in no event shall said annual
rate exceed the maximum legal interest rate for corporations. Such royalty payment, when made,
shall be accompanied by all interest so accrued.

7.04

LICENSEE shall keep full and accurate books and records setting forth the volume of LICENSED
PRODUCT distributed free of charge, gross sales in units and values and deductions therefrom in
computing NET SALES and the amount of royalties accrued. Upon LICENSOR’s request, LICENSEE shall
permit LICENSOR, at LICENSOR’s expense, by independent certified public accountant reasonably
acceptable to LICENSEE, to examine such books and records at any reasonable time, but not later
than *** following the date of any such reports, accountings, and payments and not more frequently
than ***.

12

 

7.05

Any taxes, imposts, withholdings or other amounts required by law to be paid or withheld by
LICENSEE for the account of LICENSOR, on amounts payable to LICENSOR under this AGREEMENT, shall be
deducted at the rates specified by the applicable law, provided that LICENSEE shall promptly
provide LICENSOR with receipts from the tax authorities evidencing payment of such taxes. LICENSEE
shall take all commercially reasonable steps at LICENSOR’s request and sole cost in order to allow
LICENSOR to take advantage of the relevant double taxation treaty(ies) for the purpose of avoiding
or minimizing withholding taxes on such amounts, if any.

Article 8.00 — Representations and Warranties

8.01

LICENSEE represents and warrants, on its own behalf and on behalf of its AFFILIATES, to LICENSOR
that as of the EFFECTIVE DATE:

	(a)	 	LICENSEE is a corporation duly organized, validly existing and in good standing under the
laws of state of Delaware.
	 
	(b)	 	The execution, delivery and performance of this AGREEMENT has been fully authorized by the
Board of Directors of LICENSEE, and there is no hindrance, by law, agreement or otherwise,
preventing it from entering into this AGREEMENT or from performing fully its obligations
thereunder. This AGREEMENT has been duly executed and delivered by LICENSEE and constitutes
its legal, valid and binding obligation, enforceable against it in accordance with the terms
thereof. LICENSEE has the full right to enter into this AGREEMENT and to fully perform its
obligations hereunder. LICENSEE has not previously granted, and during the TERM will not
knowingly make any commitment or grant any rights which are in conflict in any material way
with the rights and licenses granted herein. LICENSEE will not, during the TERM, encumber its
interest in the LICENSED TECHNOLOGY with liens, mortgages, security interests or another
similar interest that would give the holder the right to convert the interest into patent or
other intellectual property ownership, unless the encumbrance is expressly subject to the
licenses herein.

13

 

	(c)	 	Neither the execution and delivery of this AGREEMENT nor the consummation of the transactions
contemplated hereby will (i) violate or result in a breach of or default under (A) any of the
present provisions of its governing instruments, or (B) any mortgage, indenture, contract,
agreement, license, franchise, permit, instrument, trust, power, judgment, decree, order,
ruling or statute or regulation to which it is presently a party or by which it or its
properties may be bound, (ii) result in the creation or imposition of any lien, claim, charge,
restriction or encumbrance of any kind whatsoever upon, or give to any other person any
interest or right (including any right of termination or cancellation) in or with respect to
any of its properties, assets, business, agreements or contracts, or (iii) require any
consent, approval or waiver of, filing with, or notification to any person (including, without
limitation, any governmental authority), not heretofore obtained or effected, except
regulatory filings and approvals contemplated in the performance of this AGREEMENT.

8.02

LICENSOR represents and warrants, on its own behalf and on behalf of its AFFILIATES, to LICENSEE
that as of the EFFECTIVE DATE:

	(a)	 	LICENSOR is a corporation duly organized, validly existing and in good standing under the
laws of Italy.
	 
	(b)	 	The execution, delivery and performance of this AGREEMENT has been fully authorized by the
Board of Directors of LICENSOR, and there is no hindrance, by law, agreement or otherwise,
preventing it from entering into this AGREEMENT or from performing fully its obligations
thereunder. This AGREEMENT has been duly executed and delivered by LICENSOR and constitutes
its legal, valid and binding obligation, enforceable against it in accordance with the terms
thereof. LICENSOR has the full right to enter into this AGREEMENT, and to fully perform its
obligations hereunder. LICENSOR has not previously granted, and during the TERM will not make
any commitment or grant any rights which are in conflict in any material way with the rights
and licenses granted herein. LICENSOR will not, during the TERM, encumber its interest in the
LICENSED TECHNOLOGY with liens, mortgages, security interests or another similar interest that
would give the holder the right to

14

 

	 	 	convert the interest into patent or other intellectual
property ownership, unless the encumbrance is expressly subject to the licenses herein.

	(c)	 	Neither the execution and delivery of this AGREEMENT nor the consummation of the transactions
contemplated hereby will (i) violate or result in a breach of or default under (A) any of the
present provisions of its governing instruments, or (B) any mortgage, indenture, contract,
agreement, license, franchise, permit, instrument, trust, power, judgment, decree, order,
ruling or statute or regulation to which it is presently a party or by which it or its
properties may be bound, (ii) result in the creation or imposition of any lien, claim, charge,
restriction or encumbrance of any kind whatsoever upon, or give to any other person any
interest or right (including any right of termination or cancellation) in or with respect to
any of its properties, assets, business, agreements or contracts, or (iii) require any
consent, approval or waiver of, filing with, or notification to any person (including, without
limitation, any governmental authority), not heretofore obtained or effected, except
regulatory filings and approvals contemplated in the performance of this AGREEMENT.
	 
	(d)	 	LICENSOR is the legal and beneficial owner of, or CONTROLS, and has the unencumbered right to
license to LICENSEE in the manner set forth in this AGREEMENT, the LICENSED TECHNOLOGY in the
TERRITORY and no further approvals or consents are required to effect such license which have
not been obtained.
	 
	(e)	 	The LICENSED TECHNOLOGY constitute all of the intellectual property that is CONTROLLED by
LICENSOR and used in the development, manufacture or commercialization of LICENSED PRODUCT
and, to LICENSOR’s knowledge, the development, manufacture or commercialization of LICENSED
PRODUCT in the TERRITORY does not infringe the INTELLECTUAL PROPERTY RIGHTS of any THIRD
PARTY.
	 
	(f)	 	There are no claims, judgments or settlements against or owed by LICENSOR, nor any pending
reissue, reexamination, interference, opposition or similar proceedings, with respect to the
LICENSED TECHNOLOGY, and LICENSOR has not received written notice as of the EFFECTIVE DATE of
any threatened claims or litigation or any reissue, reexamination, interference, opposition or
similar proceedings seeking to invalidate or otherwise challenge the LICENSED TECHNOLOGY.

15

 

	(g)	 	LICENSOR undertakes to use all COMMERCIALLY REASONABLE EFFORTS to maintain the confidential
status, including, where applicable, the trade secret status, of all LICENSED KNOW-HOW.
	 
	(h)	 	LICENSOR and its AFFILIATES have not been debarred or subject to debarment pursuant to
Section 306 of the United States Federal Food, Drug and Cosmetic Act, or subject of a
conviction described in such Section 306.

8.03

THE LIMITED WARRANTIES CONTAINED IN THIS ARTICLE 8.00 ARE THE SOLE WARRANTIES GIVEN BY THE PARTIES
WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT AND ARE MADE EXPRESSLY IN LIEU OF AND EXCLUDE
ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE
MANUFACTURE, USE AND/OR SALE OF THE LICENSED PRODUCT IN THE TERRITORY, WILL NOT INFRINGE ANY
PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS HELD BY A THIRD PARTY.
ALL OTHER IMPLIED REPRESENTATIONS AND WARRANTIES PROVIDED BY COMMON LAW, STATUTE OR OTHERWISE ARE
HEREBY DISCLAIMED BY BOTH PARTIES.

Article 9.00 — Liability

9.01

Each party shall notify the other if it becomes aware of any claims, actions, suits, losses,
liability costs or expenses alleged to be caused by or resulting from the use or consumption of the
LICENSED PRODUCT in the TERRITORY (“CLAIMS”). LICENSOR and LICENSEE shall cooperate to the extent
possible, in the defense of any such CLAIMS, and each party may, at its expense, have counsel of
its choice present at proceedings on any such CLAIMS or negotiations pertaining thereto. Neither
party shall take any action with respect to such CLAIMS to materially prejudice the interest of the
other party. As to any such CLAIMS in which a party is named as a party, defendant, or is or could
be liable, each party

16

 

agrees that no settlement of any such CLAIMS shall be concluded without the
prior consent of the other party, which consent shall not be unreasonably withheld.

9.02

LICENSEE shall indemnify and hold LICENSOR and its AFFILIATES, and their officers, directors and
employees, free and harmless from any loss, damage, claim, suit, cost or expense (including
attorneys’ fees) arising from (i) *** *** ***.

9.03

LICENSOR shall indemnify and hold LICENSEE and its AFFILIATES, and their officers, directors and
employees, free and harmless from any loss, damage, claim, suit, cost or expense (including
attorney’s fees) arising from ***.

9.04

During the TERM and for a period of *** thereafter, each party at its sole expense, shall obtain
and/or maintain insurance, including, but not limited to, product liability insurance in such
amount as is reasonable and adequate given its responsibilities and liabilities under this
AGREEMENT and the product and country the subject of this AGREEMENT. Upon request, each party shall
provide the other party with a duplicate original copy of such insurance policy.

9.05

Notwithstanding any provision to the contrary in this AGREEMENT, in no event (including fault,
negligence or strict liability of either party) shall either party be liable to the other for
indirect, incidental or consequential or punitive damages or loss of profit or loss of use related
to any claim, cause of action, proceedings or judgement arising in connection with this AGREEMENT.

9.06

The provisions of this Article 9.00 shall survive the termination or expiration of this AGREEMENT.

17

 

Article 10.00 — LICENSED TECHNOLOGY

10.01

LICENSEE shall market and sell the LICENSED PRODUCT in the TERRITORY, using exclusively the
LICENSED TRADEMARK. Without prejudice to the above provisions, in the event that LICENSEE
reasonably determines to use another trademark other than the LICENSED TRADEMARK to market and sell
the LICENSED PRODUCT in the TERRITORY (“OTHER TRADEMARK”), LICENSEE shall be entitled to do so and
LICENSEE shall own such OTHER TRADEMARK. In the event LICENSEE markets and sells the LICENSED
PRODUCT under the OTHER TRADEMARK, then during the TERM, and after its termination for any reason
whatsoever, LICENSOR shall not, directly or indirectly, use, file or register the OTHER TRADEMARK
or trade name identical with or confusingly similar to the OTHER TRADEMARK.

10.02

To the extent permitted by applicable law and regulation, the parties hereby agree that the
packaging of the LICENSED PRODUCT, as well as the written promotional materials used by LICENSEE in
the TERRITORY for the LICENSED PRODUCT, shall bear the legend “Under license of Chiesi Farmaceutici
S.p.A.”. Notwithstanding the foregoing, all packaging and promotional materials used by LICENSEE
with respect to the LICENSED PRODUCT shall fully comply with applicable laws where sold in the
TERRITORY. Without prejudice to the foregoing, samples of all packaging and written promotional
materials, solely to the extent related to the LICENSED PRODUCT, shall be ***.

10.03

LICENSEE acknowledges the validity of LICENSOR’s right, title and interest in and to the LICENSED
TECHNOLOGY and LICENSOR may terminate this AGREEMENT in accordance with the provisions of Section
12.02 herein below if LICENSEE takes any action which:

	 	10.03.01	 	- materially impairs any such right, title or interest in the TERRITORY; or

18

 

	 	10.03.02	 	- challenges the validity, scope or enforceability of the LICENSED TRADEMARK, or
the substantial and secret nature of the LICENSED KNOW HOW, each in the TERRITORY.

10.04

During the TERM, and after its termination for any reason whatsoever, LICENSEE shall not, directly
or indirectly, use, file or register any trademark or trade name identical with or confusingly
similar to the LICENSED TRADEMARK, provided the above prohibition shall not apply with respect to
the OTHER TRADEMARK. Furthermore, during the TERM, and after its termination for any reason
whatsoever, LICENSEE shall not apply, before any authority of any country, for the registration of
any internet domain name (nor any other creative expression that may be the subject of
registration), containing, in any form or graphic character, the name “CHIESI” and/or the LICENSED
TRADEMARK (excluding the OTHER TRADEMARK) used hereunder (and/or any other denomination confusingly
similar to the aforesaid names).

10.05

Forthwith, on termination of this AGREEMENT, LICENSEE shall cease all use of the LICENSED TRADEMARK
in connection with, or in relation to, the LICENSED PRODUCT except to the extent necessary for
sales permitted under Section 12.06 (a) below.

10.06

LICENSOR and LICENSEE shall promptly notify each other of any infringement of the LICENSED
TECHNOLOGY, which may come to their attention. *** may, at its option, undertake reasonable efforts
to obtain discontinuance of the aforesaid infringement and, if not successful, *** may at its
option bring suit against such infringer, at its own expense. Any monetary award received as a
result of proceedings contemplated by this Section 10.06 shall first be used to compensate *** and
*** for their respective reasonable expenses incurred in connection with such proceedings (provided
that if the monetary award is not sufficient to compensate both *** and *** for their reasonable
expenses incurred in connection with such proceedings, then such monetary award shall be
apportioned pro-rata based on the reasonable expenses of each of the parties). Any award monies
remaining after such reimbursement shall be equally shared between the parties. No settlement or
consent judgment or other voluntary

19

 

final disposition of a suit under this Section 10.06 may be
entered into by either party without the prior written consent of the other party, such consent not
to be unreasonably withheld.

If *** elects not to undertake or stop undertaking reasonable efforts in order to obtain a
discontinuance of said infringement within a reasonable amount of time and/or elects not to bring
suit against such THIRD PARTY, *** shall promptly notify *** in writing of its election, and of the
circumstance of such infringement. In such event *** shall have the right, but not the obligation,
to take any and all action, at its own cost and expense, to obtain a discontinuance of the alleged
infringement and/or to bring suit against such THIRD PARTY. Any monetary award received as a result
of proceedings contemplated by this Section 10.06 shall first be used to compensate *** and *** for
their respective reasonable expenses incurred in connection with such proceedings (provided that if
the monetary award is not sufficient to compensate both *** and *** for their reasonable expenses
incurred in connection with such proceedings, then such monetary award shall be apportioned
pro-rata based on the reasonable expenses of each of the parties). Any award monies remaining after
such reimbursement shall be added to NET SALES for the calendar quarter in which they are received
and then dealt with in the manner prescribed in this AGREEMENT. No settlement or consent judgment
or other voluntary final disposition of a suit under this Section 10.06 may be entered into by
either party without the prior written consent of the other party, such consent not to be
unreasonably withheld. Each party shall execute such legal papers in connection with the foregoing
as may be reasonably requested by the other party.

The parties shall reasonably cooperate with each other in all actions or proceedings described in
this Section 10.06, to the extent pertaining to an alleged infringement. The non-controlling party
agrees to be joined as a party plaintiff if necessary to prosecute the action or proceeding and
shall provide all reasonable cooperation (including any necessary use of its name) required to
prosecute such litigation; provided that the controlling party shall reimburse the non-controlling
party for out-of-pocket expenses reasonably incurred in providing such cooperation at the
controlling party’s request. The non-controlling party will be entitled to be represented by
counsel of its own choice at its own expense.

20

 

10.07

In the event of any claim, threat or suit by a THIRD PARTY against either LICENSEE or LICENSOR
alleging infringement by the LICENSED PRODUCT of any patents or other INTELLECTUAL PROPERTY RIGHTS
of such THIRD PARTY, the party receiving such notice shall promptly notify the other party in
writing of such fact, and the parties shall defend in close cooperation with each other against
such claim, threat or suit.

10.08

In the event that a conflict arises between the interests of LICENSOR and LICENSEE in any
litigation described in this Article 10.00, the party that is not funding the litigation shall have
the right to be represented by counsel of its own choice and at its sole expense.

Article 11.00 — Confidentiality

11.01

Except as otherwise provided in this Article 11, LICENSEE undertakes to maintain in strict
confidence and secret and not to disclose to others, except insofar as it may be necessary in
carrying out the purposes of this AGREEMENT and to bind its employees to hold to confidence and
secret, the LICENSED TECHNOLOGY and any other information and data of a confidential nature which
will be furnished to LICENSEE by or on behalf of LICENSOR pursuant to this AGREEMENT. The
obligation of confidentiality shall remain in force for *** after any termination or expiration of
this AGREEMENT, provided, that such obligation shall not terminate or expire to the extent that
such confidential information relates to a trade secret, unless the provisions of Section 11.05
below shall apply.

11.02

Except as otherwise provided in this Article 11, LICENSOR undertakes to maintain in strict
confidence and secret and not to disclose to others, except insofar as it may be necessary in
carrying out the purposes of this AGREEMENT and to bind its employees to hold to confidence and
secret, any information and data of a confidential nature which will be furnished to LICENSOR by or
on behalf of LICENSEE pursuant to this AGREEMENT. The obligation of confidentiality shall remain in
force for *** after any termination or

21

 

expiration of this AGREEMENT, provided, that such obligation
shall not terminate or expire to the extent that such confidential information relates to a trade
secret, unless the provisions of Section 11.05 below shall apply.

11.03

LICENSOR recognizes that LICENSEE and/or its AFFILIATES may need to publish or otherwise present
the methods and results of clinical trial activities undertaken pursuant to this AGREEMENT and
agrees that LICENSEE and/or its AFFILIATES shall be permitted to
present at conferences, symposia and professional meetings and to publish in journals and other
publications, methods and results of clinical trials, provided, however, that ***.

11.04

Notwithstanding the foregoing, in the event that either party receives a request to disclose all or
any part of the confidential information of the other party under the terms of a valid and
effective subpoena or order issued by a court of competent jurisdiction, such party agrees to (i)
immediately notify the other party of the existence, terms and circumstances surrounding such a
request, and (ii) consult with the other party on the advisability of taking legally available
steps to resist or narrow such request, and (iii) if disclosure of such information is required,
exercise ALL COMMERCIALLY REASONABLE EFFORTS to obtain an order or other reliable assurance that
confidential treatment will be accorded to such portion of the undisclosed information which the
other party so designates.

11.05

The obligations of non-disclosure and non-use set forth in this Article 11 shall not apply to
confidential information which:

	(a)	 	was, at the time of disclosure, in the possession of the receiving party (as evidenced by its
written records) and was not previously acquired from or on behalf of the disclosing party on
a confidential basis,
	 
	(b)	 	was in the public domain prior to disclosure, or became, after disclosure, publicly known
through no fault of the receiving party or any person to whom the receiving party directly or
indirectly provided such confidential information,
	 
	(c)	 	was received from a THIRD PARTY who rightfully made such disclosure,

22

 

	(d)	 	was approved for use or release by written authorization from the disclosing party prior to
such use or release by the receiving party,
	 
	(e)	 	is required to be disclosed by operation of law, governmental regulation or court order
provided the receiving party gives the disclosing party written notice of such required
disclosure prior to making such disclosure, and the receiving party uses all reasonable effort
to cooperate in securing confidential protection for such information; or
	 
	(f)	 	is required to be disclosed to any governmental authority or regulatory authority to the
extent that such disclosure is reasonably necessary to obtain authorizations to conduct a
clinical trial with, to manufacture and to market commercially products based on the LICENSED
TECHNOLOGY, provided the disclosing party is otherwise entitled to
engage in such activities under this AGREEMENT and provided that confidentiality is in any
case maintained on such confidential information to the extent permitted by any such
authority.

Any specific confidential information shall not be deemed to fall within Section 11.05 (a), (b),
(c), (d), (e) or (f) above merely because it falls within the scope of more general information
within one of these exceptions.

Article 12.00 — Term and Termination 

12.01

This AGREEMENT shall become effective on the EFFECTIVE DATE and shall remain in force for a term of
10 (ten) years starting from the FIRST COMMERCIAL SALE in the TERRITORY, on a country-by-country
basis (the “TERM”). Thereafter, LICENSEE shall have a paid-up, royalty-free, *** license under the
LICENSED TECHNOLOGY to use, develop, make and have made (including, manufacturing and packaging),
register, store, handle, market, promote, distribute, sell and/or offer for sale the LICENSED
PRODUCT and IMPROVEMENTS (owned or CONTROLLED by LICENSOR) in the LICENSED FIELD in the TERRITORY.

12.02

In the event that LICENSEE or LICENSOR substantially defaults or breaches any material provision of
this AGREEMENT, the other party shall have the right to terminate this

23

 

AGREEMENT upon *** written notice to the other party, provided, however, that if the party in question cures such default or
breach, or presents a commercially reasonable plan providing a reasonably short timeline for cure
of such default or breach, within said *** period, then this AGREEMENT shall continue in full force
and effect. Without limitations breaches of Section 10.03 and Article 11 herein above are incapable
of cure.

12.03

In the event that either party:

	(i)	 	is adjudicated as bankrupt or insolvent and, if such adjudication be involuntary, it is not
vacated within ***; or
	 
	(ii)	 	any proceeding is commenced by or against such party seeking relief under any bankruptcy or
insolvency law and if such proceeding be involuntary, it remains undismissed for ***; or such
party, by action or answer, approves of, consents to or acquires in such proceeding or admits
the material allegations of or defaults in answering a petition filed in such proceeding; or
	 
	(iii)	 	admits in writing its inability to pay its debts as they become due; or
	 
	(iv)	 	makes an assignment for the benefit of creditors;

then, in any such case, such party shall be deemed in default hereunder and the other party shall
have the right, upon *** prior notice, to terminate this AGREEMENT.

12.04

In the event, through no fault of LICENSOR or otherwise due to applicable laws or factors beyond
its reasonable control, LICENSEE has not filed an NDA in the US and/or an NDS in Canada by ***,
LICENSOR shall have the right to *** terminate this Agreement with respect to such country/ies upon
a *** prior written notice; provided, however, that if LICENSEE files the NDA and/or NDS
within said *** period, then this AGREEMENT shall continue in full force and effect; further
provided, that in the event that LICENSEE has a good faith belief that it can file the NDA and/or
NDS, but requires a commercially

24

 

reasonable extension of the requisite timelines, the parties shall
make good faith efforts to meet and discuss such extension.

12.05

“CHANGE OF CONTROL” means, with respect to a party, (a) the acquisition (directly or
indirectly, whether by merger, consolidation, purchase and sale, share exchange or otherwise) by a
THIRD PARTY (other than an AFFILIATE or any trust or fund created under a profit-sharing or other
benefit plan for employees of the party undergoing the acquisition) of a beneficial interest in the
securities of such party representing more than fifty percent (50%) of the combined voting power of
the party’s then outstanding securities; or (b) the transfer, sale or assignment of more than fifty
percent (50%) of the assets of such party to a THIRD PARTY.

	(i)	 	Notwithstanding Section 2.03 above, in the event that LICENSEE is subject to a CHANGE OF
CONTROL with a THIRD PARTY, which THIRD PARTY was, at the date of such CHANGE OF CONTROL,
marketing, promoting and/or selling a LICENSEE COMPETING PRODUCT then, within *** of the
completion of such CHANGE OF CONTROL to be communicated in writing by LICENSEE to LICENSOR,
LICENSEE shall provide written notification to LICENSOR specifying election of one of the
following two (2) alternatives:

	 	(a)	 	LICENSEE accepts to divest such LICENSEE COMPETING PRODUCT within a period of
*** following the completion date of such CHANGE OF CONTROL; or
	 
	 	(b)	 	LICENSEE elects to terminate this AGREEMENT which shall become effective ***
from such notification of LICENSEE’s election to terminate the AGREEMENT in its
entirety.

	(ii)	 	In the event that LICENSEE is subject to a CHANGE OF CONTROL with a THIRD PARTY, which, at the
date of such CHANGE OF CONTROL is in material litigation with LICENSOR, LICENSOR shall be entitled
to cause LICENSEE to elect Section 12.05(i)(b) above.

25

 

	(iii)	 	In the event of a CHANGE OF CONTROL of LICENSOR, LICENSOR shall continue to be bound by all
terms and conditions of this AGREEMENT, including the provisions of Section 11.02 above.

12.06

Upon termination of this AGREEMENT pursuant to Section 3.01 A. or 12.05, or by LICENSOR pursuant to
Section 6.01, 12.02 or 12.04:

	(a)	 	LICENSEE shall promptly cease selling the LICENSED PRODUCT (except LICENSED PRODUCT currently
in stock) and using the LICENSED TECHNOLOGY;
	 
	(b)	 	LICENSEE shall promptly return or transfer free of charge to LICENSOR, with external
administrative expenses, if any, to be paid by LICENSOR, all pharmacological, toxicological
and clinical original data in its possession and all technical information, and LICENSED
TECHNOLOGY or material relating to the LICENSED PRODUCT in its possession; and
	 
	(c)	 	LICENSEE shall promptly transfer free of charge to LICENSOR, with external administrative
expenses, if any, to be paid by LICENSOR, or to a company designated by LICENSOR any IND, NDA,
NDS and other authorizations obtained with respect to the LICENSED PRODUCT.

12.07

Upon termination of this AGREEMENT for any reason whatsoever:

	(a)	 	Sections 7.04, 10.01 (last sentence only) and 10.04 and Articles 9.00, 11.00, 14.00, 16.00,
17.00, 18.00, 19.00, 20.00, 21.00, 22.00 and 23.00 shall survive termination of this
AGREEMENT;
	 
	(b)	 	Except as herein otherwise provided all other rights and obligations of the parties to each
other shall terminate, provided, however, that LICENSEE shall not be released from the
liability to make any and all outstanding payments to LICENSOR.

26

 

	 	 	Termination of this AGREEMENT for any reason shall not release any party from any liability,
obligation or agreement which has already accrued nor affect the survival of any provision
hereof which is expressly stated to survive such termination.

Article 13.00 — Assignment

13.01

Either party may assign or transfer the rights granted to it under this AGREEMENT to an AFFILIATE
in the TERRITORY, as required to enable such party to fulfill the purposes thereof, provided that
such party shall guarantee the performance of all obligations of such AFFILIATE arising out of or
resulting from this AGREEMENT. Without prejudice to the provisions of Sections 2.01 and 2.02 above,
***. Subject to Section 12.05 above, but notwithstanding the foregoing, either party may assign
this AGREEMENT to a THIRD PARTY in connection with the sale or transfer of all or substantially all
of its assets with respect to the business (whether by merger, asset sale or otherwise) to which
this AGREEMENT is related to such THIRD PARTY.

Article 14.00 — Notice

14.01

Notices to LICENSEE shall be addressed to:

Eurand Pharmaceuticals Inc.

790 Township Line Road, Suite 250

Yardley, Pennsylvania 19067

USA

Telephone number: +1.267.759.9322

Telecopy: +1.215.968.2941

Attention: General Counsel

And notices to LICENSOR shall be addressed to:

27

 

Chiesi Farmaceutici S.p.A.

Via Palermo 26/A

43100 Parma

ITALY

Phone: +39.0521.2791

Fax: +39.0521.774468

Attention: Managing Director

Copy to: Corporate Licensing Director + Legal and Corporate

Affairs Director

Either party may change its address by giving notice to the other party.

14.02

Any notice required or provided for by the terms of this AGREEMENT shall be in writing and sent by
registered mail, prepaid and properly addressed in accordance with Section 14.01.

Article 15.00 — Force Majeure

15.01

Failure of either party to perform its obligations under this AGREEMENT (excepting the obligation
to make payments) shall not subject such party to any liability to the other if such failure is
caused or occasioned by act of God, or public enemy, fire, explosion, flood, drought, war, riot,
sabotage, embargo, strikes, or other labour trouble, interruption of, or delay in transportation,
compliance with any order, regulation or request of any government of competent jurisdiction or any
officer, department, agency, including regulatory agency, or committee thereof, which compliance
has also caused a delay in the performance hereunder, or by compliance with a request authorized by
such government authority of any manufacturer for material to be used by it, or by any other event
or circumstance of like or different character to the forgoing beyond the reasonable control of the
party so failing. The party suffering an event of force majeure shall immediately notify the other
party and both parties will cooperate in good faith in order to minimize the damages for both
parties; provided, however, that the party whose performance has not been hindered by the force
majeure shall have the right to terminate this AGREEMENT upon *** prior notice to the other, such
notice to take effect only if an event of force majeure continues for more ***. Termination
pursuant

28

 

to the application of this Section 15.01 shall not constitute a material breach of this AGREEMENT
on the part of either party.

Article 16.00 — Governing Law

16.01

This AGREEMENT shall be governed by and construed according to the laws of ***, without regard to
the principles of conflicts of law.

Article 17.00 — Jurisdiction

17.01

In the event of any controversy or claim arising out of or relating to any provision of this
AGREEMENT or breach thereof, the parties shall try to settle those conflicts amicably between
themselves. Should they fail to agree, the parties hereby agree to resolve any controversy or claim
arising from this AGREEMENT (“DISPUTE”) by submitting such DISPUTE to arbitration under the Rules
of Arbitration of International Chamber of Commerce (“ICC”). Unless, the parties agree otherwise
in writing, the number of arbitrators shall be three. One arbitrator shall be appointed by each
party and the third arbitrator shall be appointed by the International Court of Arbitration of the
ICC. The place of arbitration will be Milan, Italy. The language of the arbitration will be in
English. Prior to the commencement of hearings, each of the arbitrators appointed must provide an
oath of undertaking of impartiality. Judgment upon the award rendered by the arbitrators may be
entered into any court having jurisdiction thereof. The cost of any such arbitration will be
divided equally between the parties, with each party bearing its own attorneys’ fees and costs.
The arbitration proceedings and the decision of the arbitrators will be kept confidential by the
parties and the arbitrators.

29

 

Article 18.00 — Entire Agreement 

18.01

This AGREEMENT constitutes the entire agreement between the parties hereto with respect to the
subject matter and supersedes all previous agreements and understandings, whether written or oral.
No modification or alteration shall be binding unless in writing and signed by both parties.

Article 19.00 — Fees and Expenses

19.01

Except as otherwise expressly provided in this AGREEMENT, each of the parties shall bear and pay
all fees, costs and expenses incurred by it in connection with the origin, preparation,
negotiation, execution and delivery of this AGREEMENT and the transactions and other agreements and
documents contemplated hereby (whether or not such transactions are consummated), including,
without limitation, any fees, expenses or commissions of its representatives.

Article 20.00 — Severability and No Waiver

20.01

The parties hereto are desirous of adhering faithfully to the laws and formalities (including
fiscal formalities) to which each is subject. Should any provision of this AGREEMENT be held to be
unenforceable or otherwise in conflict with or in violation of such laws, the remainder of this
AGREEMENT shall remain binding upon the parties and only those provisions shall be deemed to be
null and void.

30

 

20.02

The waiver by either party of any right hereunder, or of a failure to perform, or of a breach by
the other party, shall not be deemed a waiver of any other right hereunder, or of any other breach
or failure by said party, whether of a similar nature or otherwise.

Article 21.00 — Negation of Agency

21.01

It is understood and agreed that neither party is by this AGREEMENT or anything herein contained,
constituted or appointed the agent or representative of the other party for any purpose whatsoever,
nor shall anything herein contained be deemed or construed as granting to a party any right or
authority to assume or to create any obligation or responsibility, express or implied, for or on
behalf of, or in the name of the other party, or to bind the other party in any way or manner
whatsoever.

Article 22.00 — Headings 

22.01

Headings are inserted for convenience and shall not by themselves determine the interpretation of
this AGREEMENT.

Article 23.00 — Publicity

23.01

All public notices to THIRD PARTIES and all other publicity concerning the transactions
contemplated by this AGREEMENT, including the existence or any of the terms and conditions thereof,
shall be jointly planned and coordinated by LICENSEE and LICENSOR and no party shall act
unilaterally in this regard without the prior written approval of the other party (such approval
not to be unreasonably withheld), except with regard to disclosures made in order to comply with
law or government or stock exchange regulations; provided, however,

31

 

that the other party shall have an opportunity to review and promptly comment on such disclosures
before they are made and the parties shall agree on the provisions of this AGREEMENT for which the
parties shall seek confidential treatment, it being understood that if one party determines to seek
confidential treatment for a provision for which the other party does not, then the parties will
use reasonable efforts in connection with such filing to seek the confidential treatment of any
such provision. The parties shall cooperate, each at its own reasonable expense, in such filing,
registration or notification, including without limitation such confidential treatment request, and
shall execute all documents reasonably required in connection therewith.

IN WITNESS THEREOF, the parties hereto have caused this AGREEMENT to be duly executed in duplicate
by their authorized officers as of the EFFECTIVE DATE.

	 	 	 
	CHIESI FARMACEUTICI S.p.A.

	 	EURAND PHARMACEUTICALS INC.
	 
	 	 
	/s/ Dr. Alberto Chiesi 
	 	/s/ Mr. Gearoid M. Faherty
	 

	 	 
	 
	 	 
	Dr. Alberto Chiesi

	 	Mr. Gearoid M. Faherty
	 
	 	 
	President & Chief Executive Officer

	 	Chief Executive Officer

32

 

APPENDIX A

To the License Agreement dated April 2, 2008 and signed between CHIESI FARMACEUTICI S.p.A. and
EURAND PHARMACEUTICALS INC.

DEVELOPMENT PLAN OUTLINE

***

	 	 	 
	CHIESI FARMACEUTICI S.p.A.

	 	EURAND PHARMACEUTICALS INC.
	 
	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	(signature)

	 	(signature)

33

 

APPENDIX B

To the License Agreement dated April 2, 2008 and signed between CHIESI FARMACEUTICI S.p.A. and
EURAND PHARMACEUTICALS INC.

LICENSED TRADEMARK

***

	 	 	 
	CHIESI FARMACEUTICI S.p.A.

	 	EURAND PHARMACEUTICALS INC.
	 
	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	(signature)

	 	(signature)

34

 

APPENDIX C

To the License Agreement dated April 2, 2008 and signed between CHIESI FARMACEUTICI S.p.A. and
EURAND PHARMACEUTICALS INC.

	 	•	 	Complete dossier of MRP 1st wave Marketing Authorization Application (MAA),
including any interaction (pre and post submission) with the concerned regulatory
authority, includes Response Document to the questions raised by the concerned member
states.
	 
	 	•	 	Complete documentation relevant to any variation, renewal or additional application
relevant to the Marketing Authorization granted in the EU.
	 
	 	•	 	Complete Pharmacovigilance data/PSURs and post approval clinical studies.
	 
	 	•	 	All further correspondence with any regulatory authority relevant to any module of the
MAAs dossier.
	 
	 	•	 	Any data related to the product not included in the MAAs dossier (i.e. complete
documentation relevant to any data generated during product development).
	 
	 	•	 	All clinical development plans and data generated — retrospective and current: to be
updated on an ongoing basis.
	 
	 	•	 	Any freedom to operate searches (a list of the most pertaining documents emerged from
our searches already provided on the occasion of the Due Diligence process)
	 
	 	•	 	All marketing materials (if relevant — according to field of use — to be provided in
due course).
	 
	 	•	 	Any additional information covered under the term “LICENSED KNOW HOW” and to be updated
with new “KNOW HOW” as it is generated.

	 	 	 
	CHIESI FARMACEUTICI S.p.A.

	 	EURAND PHARMACEUTICALS INC.
	 
	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	(signature)

	 	(signature)

35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]